BioMarin Pharmaceutical (BMRN) 10-K26 Feb 242023 FY Annual reportFinancial data

Company Profile

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
Cover Page - USD ($) $ in Billions	Dec. 31, 2023	Feb. 16, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	000-26727
Entity Registrant Name	BioMarin Pharmaceutical Inc
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	68-0397820
Entity Address, Address Line One	770 Lindaro Street
Entity Address, City or Town	San Rafael
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94901
City Area Code	415
Local Phone Number	506-6700
Title of 12(b) Security	Common Stock, par value $.001
Trading Symbol	BMRN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction Flag	false
Entity Shell Company	false
Entity Public Float			$ 10.1
Entity Common Stock, Shares Outstanding		188,675,622
Documents Incorporated by Reference	Documents Incorporated by Reference: Specified portions of the registrant's definitive proxy statement for the registrant's 2024 annual meeting of stockholders, which will be filed with the Commission no later than 120 days after the end of the registrant's fiscal year ended December 31, 2023, are incorporated by reference under Part III of this Annual Report on Form 10-K.
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Central Index Key	0001048477

Audit Information

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2023
Audit Information [Abstract]
Auditor Firm ID	185
Auditor Name	KPMG LLP
Auditor Location	San Francisco, California

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 755,127	$ 724,531
Short-term investments	318,683	567,006
Accounts receivable, net	633,704	461,316
Inventory	1,107,183	894,083
Other current assets	141,391	104,521
Total current assets	2,956,088	2,751,457
Noncurrent assets:
Long-term investments	611,135	333,835
Property, plant and equipment, net	1,066,133	1,073,366
Intangible assets, net	294,701	338,569
Goodwill	196,199	196,199
Deferred tax assets	1,545,809	1,505,412
Other assets	171,538	176,236
Total assets	6,841,603	6,375,074
Current liabilities:
Accounts payable and accrued liabilities	683,147	572,959
Short-term convertible debt, net	493,877	0
Short-term contingent consideration	0	15,925
Total current liabilities	1,177,024	588,884
Noncurrent liabilities:
Long-term convertible debt, net	593,095	1,083,019
Other long-term liabilities	119,935	100,015
Total liabilities	1,890,054	1,771,918
Stockholders’ equity:
Common stock, $0.001 par value: 500,000,000 shares authorized; 188,598,154 and 186,250,719 shares issued and outstanding, respectively	189	186
Additional paid-in capital	5,611,562	5,404,895
Company common stock held by the Nonqualified Deferred Compensation Plan	(9,860)	(8,859)
Accumulated other comprehensive loss	(28,788)	(3,867)
Accumulated deficit	(621,554)	(789,199)
Total stockholders’ equity	4,951,549	4,603,156
Total liabilities and stockholders’ equity	$ 6,841,603	$ 6,375,074

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	188,598,154	186,250,719
Common stock, shares outstanding (in shares)	188,598,154	186,250,719

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
REVENUES:
Total revenues	$ 2,419,226	$ 2,096,039	$ 1,846,275
OPERATING EXPENSES:
Cost of sales	514,854	483,669	470,515
Research and development	746,773	649,606	628,793
Selling, general and administrative	937,291	854,009	759,375
Intangible asset amortization and contingent consideration	62,211	67,193	69,933
Gain on sale of nonfinancial assets, net	0	(108,000)	0
Total operating expenses	2,261,129	1,946,477	1,928,616
INCOME (LOSS) FROM OPERATIONS	158,097	149,562	(82,341)
Interest income	58,339	18,034	10,482
Interest expense	(17,335)	(15,970)	(15,337)
Other income (expense), net	(10,538)	(2,050)	11,846
INCOME (LOSS) BEFORE INCOME TAXES	188,563	149,576	(75,350)
Provision for (benefit from) income taxes	20,918	8,015	(11,270)
NET INCOME (LOSS)	$ 167,645	$ 141,561	$ (64,080)
EARNINGS (LOSS) PER SHARE, BASIC (in dollars per share)	$ 0.89	$ 0.76	$ (0.35)
EARNINGS (LOSS) PER SHARE, DILUTED (in dollars per share)	$ 0.87	$ 0.75	$ (0.35)
Weighted-average common shares outstanding, basic (in shares)	187,834	185,266	182,852
Weighted average common shares outstanding, diluted (in shares)	191,595	188,963	182,852
Net product revenues
REVENUES:
Total revenues	$ 2,372,538	$ 2,042,025	$ 1,783,498
Royalty and other revenues
REVENUES:
Total revenues	$ 46,688	$ 54,014	$ 62,777

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ 167,645	$ 141,561	$ (64,080)
Available-for-sale debt securities:
Unrealized holding gain (loss) arising during the period, net of tax impact of $(3,922), $3,247 and $1,596, respectively	12,963	(10,720)	(5,262)
Cash flow hedges:
Unrealized holding gain (loss) arising during the period, net of tax impact of $0 for all periods presented	(37,720)	29,045	34,379
Less: reclassifications to net income (loss), net of tax impact of $0 for all periods presented	164	36,624	(1,454)
Net change in unrealized holding gain (loss), net of tax	(37,884)	(7,579)	35,833
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX	(24,921)	(18,299)	30,571
COMPREHENSIVE INCOME (LOSS)	$ 142,724	$ 123,262	$ (33,509)

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Unrealized holding gain (loss) arising during the period, tax	$ (3,922)	$ 3,247	$ 1,596
Unrealized holding gain (loss) arising during the period, tax	0	0	0
Reclassifications to net income (loss), tax	$ 0	$ 0	$ 0

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common stock:	Additional paid-in capital:	Company common stock held by the NQDC:	Accumulated other comprehensive income (loss):	Accumulated deficit:
Beginning balance (in shares) at Dec. 31, 2020		181,741,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans (in shares)		2,172,000
Ending balance (in shares) at Dec. 31, 2021		183,913,000
Total stockholders' equity, beginning balances at Dec. 31, 2020	$ 4,100,931	$ 182	$ 4,993,407	$ (9,839)	$ (16,139)	$ (866,680)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans, net of tax		2	3,389
Stock-based compensation			194,856
Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC)			(150)	150
Other comprehensive income (loss)	30,571				30,571
Net income (loss)	(64,080)					(64,080)
Total stockholders' equity, ending balances at Dec. 31, 2021	$ 4,265,669	$ 184	5,191,502	(9,689)	14,432	(930,760)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans (in shares)		2,338,000
Ending balance (in shares) at Dec. 31, 2022	186,250,719	186,251,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans, net of tax		$ 2	14,328
Stock-based compensation			199,895
Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC)			(830)	830
Other comprehensive income (loss)	$ (18,299)				(18,299)
Net income (loss)	141,561					141,561
Total stockholders' equity, ending balances at Dec. 31, 2022	$ 4,603,156	$ 186	5,404,895	(8,859)	(3,867)	(789,199)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans (in shares)		2,347,000
Ending balance (in shares) at Dec. 31, 2023	188,598,154	188,598,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans, net of tax		$ 3	(7,162)
Stock-based compensation			212,828
Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC)			1,001	(1,001)
Other comprehensive income (loss)	$ (24,921)				(24,921)
Net income (loss)	167,645					167,645
Total stockholders' equity, ending balances at Dec. 31, 2023	$ 4,951,549	$ 189	$ 5,611,562	$ (9,860)	$ (28,788)	$ (621,554)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 167,645	$ 141,561	$ (64,080)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	104,386	101,969	108,039
Non-cash interest expense	4,188	4,117	4,146
Amortization of premium (accretion of discount) on investments	(9,228)	3,043	5,155
Stock-based compensation	207,099	196,308	197,263
Gain on sale of nonfinancial assets, net	0	(108,000)	0
Impairment of assets	38,608	0	0
Deferred income taxes	(44,981)	(52,087)	(15,608)
Unrealized foreign exchange loss (gain)	28,446	(14,287)	(1,810)
Non-cash changes in the fair value of contingent consideration	0	1,704	8,026
Other	(365)	(2,043)	(2,629)
Changes in operating assets and liabilities:
Accounts receivable, net	(190,435)	(82,033)	65,574
Inventory	(157,058)	(68,264)	(35,060)
Other current assets	(50,335)	7,822	29,760
Other assets	(31,149)	(19,859)	(6,593)
Accounts payable and other short-term liabilities	68,853	59,018	15,689
Other long-term liabilities	23,585	6,933	(3,336)
Net cash provided by operating activities	159,259	175,902	304,536
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(96,691)	(120,959)	(95,578)
Maturities and sales of investments	864,863	619,995	691,049
Purchases of investments	(868,496)	(611,809)	(937,143)
Proceeds from sale of nonfinancial assets	0	103,325	0
Purchase of intangible assets	(10,920)	(10,581)	(23,647)
Other	0	0	(994)
Net cash used in investing activities	(111,244)	(20,029)	(366,313)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of awards under equity incentive plans	69,353	69,333	49,194
Taxes paid related to net share settlement of equity awards	(76,319)	(54,283)	(45,805)
Payments of contingent consideration	(9,475)	(31,095)	0
Principal repayments of financing leases	(2,286)	(2,605)	(3,039)
Other	0	0	(398)
Net cash used in financing activities	(18,727)	(18,650)	(48)
Effect of exchange rate changes on cash	1,308	32	(57)
NET INCREASE IN CASH AND CASH EQUIVALENTS	30,596	137,255	(61,882)
Cash and cash equivalents:
Beginning of period	724,531	587,276	649,158
End of period	755,127	724,531	587,276
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for interest	10,303	10,281	10,395
Cash paid for income taxes	73,312	54,372	18,153
SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Increase (decrease) in accounts payable and accrued liabilities related to fixed assets	164	(1,482)	(4,749)
Increase in accounts payable and accrued liabilities related to intangible assets	$ 6,904	$ 742	$ 9,428

BUSINESS OVERVIEW AND SIGNIFICA

BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES	Dec. 31, 2023
Accounting Policies [Abstract]
BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES	BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES Nature of Operations Founded in 1997, BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. The Company's robust research and development capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. Basis of Presentation These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company’s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K. Use of Estimates U.S. GAAP requires management to make estimates and assumptions that affect amounts reported on the Company’s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results. Significant Accounting Policies Cash and Cash Equivalents The Company treats highly liquid investments, readily convertible to cash, with original maturities of three months or less on the purchase date as cash equivalents. Marketable and Non-Marketable Securities Marketable Securities The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument’s underlying contractual maturity date and its availability for use in current operations. All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company’s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income (Expense), Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date. Non-Marketable Equity Securities The Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer less impairment, if any. Investments in equity securities are recorded in Other Assets on the Company's Consolidated Balance Sheets. Unrealized gains and losses are reported in Other Income (Expense), Net. The Company regularly reviews its non-marketable equity securities for indicators of impairment. Inventory Commercial Inventory The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost approach on the first-in, first out (FIFO) method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations. Inventory Produced Prior to Regulatory Approval When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&D). Property, Plant and Equipment Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&D and Selling, General and Administrative (SG&A), as appropriate, in the Consolidated Statements of Operations. Property and equipment purchased for specific R&D projects with no alternative future uses are expensed as incurred and recorded to R&D in the Consolidated Statements of Operations. Leasehold improvements Shorter of life of asset or lease term Building and improvements 20 to 50 years Manufacturing and laboratory equipment 5 to 15 years Computer hardware and software 3 to 7 years Office furniture and equipment 5 years Land improvements 10 to 20 years Land Not applicable Construction-in-progress Not applicable Leases The Company's lease portfolio primarily consists of leases for properties and equipment for administrative, manufacturing and R&D activities. The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, Right of Use (ROU) assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities. Goodwill and Intangible Assets The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations. Intangible assets with finite useful lives primarily consist of acquired intellectual property and royalty rights, regulatory approval and first commercial sales milestone payments as well as costs associated with technology transfer to qualify third-party manufacturing facilities for commercial production. Intangible assets are recorded at cost, net of accumulated amortization, and amortize over their estimated useful lives on a straight-line basis. Amortization expense is recorded in Intangible Asset Amortization and Contingent Consideration on the Company's Consolidated Statements of Operations, except for amortization expense related to the technology transfer, which is recorded in Cost of Sales. Impairment The Company assesses goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable. Goodwill is assessed for impairment by comparing the fair value of the Company’s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded. Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. Long-lived Asset Impairment The Company’s long-lived assets consist of property, plant and equipment, leased ROU assets and finite-lived intangible assets, which includes costs associated with technology transfer to qualify manufacturing facilities for commercial production. Should there be an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition to the carrying amount of the asset or asset group. Any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Impairment charges related to property, plant or equipment that are not material are recorded to depreciation expense and presented in SG&A in the Consolidated Statements of Operations. Impairment charges for finite-lived intangible assets associated with technology transfer costs that are not material are recorded to Cost of Sales in the Consolidated Statements of Operations. Impairment charges related to all other finite-lived intangible assets that are not material are recorded to Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations. Capitalized Software The Company capitalizes software development costs associated with internal use software, including external direct costs of materials and services and payroll costs for employees devoting time to a software project. Costs incurred during the preliminary project stage, as well as costs for maintenance and training, are expensed as incurred. When placed in service, implementation costs are subsequently amortized on a straight-line basis over the expected useful life of the asset. As of December 31, 2023, $30.6 million of capitalized costs associated with cloud computing arrangements were included in Other Assets on the Company’s Consolidated Balance Sheets. Revenue Recognition The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. Net Product Revenues In the U.S., the Company’s commercial products, except for PALYNZIQ and ALDURAZYME, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. PALYNZIQ is distributed in the U.S. through certain certified specialty pharmacies under the PALYNZIQ Risk Evaluation and Mitigation Strategy (REMS) and ALDURAZYME is marketed world-wide by Sanofi. Outside the U.S., the Company’s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment to the customer. The Company's payment terms vary by customer, jurisdiction or, in some instances, by product. With the exception of Sanofi and certain outcomes-based contracts, most of the Company's payment terms are based on customary commercial terms and are generally less than one year after the customer obtains control. The Company does not adjust revenue for the effects of a significant financing component for contracts if the period between the transfer of control and corresponding payment is expected to be one year or less. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company’s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues. For ALDURAZYME revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net ALDURAZYME sales by Sanofi depending on sales volume, which is included in Net Product Revenues on the Company’s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Sanofi. The Company records ALDURAZYME net product revenues based on the estimated variable consideration payable when the product is sold through by Sanofi. Actual amounts of consideration ultimately received may differ from the Company’s estimates. Differences between the estimated variable consideration to be received from Sanofi and actual payments received are not expected to be material. If actual results vary from the Company’s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known. Revenue Reserves Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government and commercial rebates, chargebacks, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, patient outcomes, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company’s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known. Government and Commercial Rebates : The Company records reserves for rebates payable under government programs, such as Medicaid, and commercial arrangements, such as managed care rebates, as a reduction of revenue at the time product revenues are recorded. The Company’s reserve calculations require estimates, including estimates of customer mix and patient outcomes, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves. Sales Returns : The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers’ limited return rights and the Company’s historical experience with returns. Because of the pricing of the Company’s commercial products, the limited number of patients and the customers’ limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material. Other Incentives : Other incentives include fees paid to the Company’s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on an eligible BioMarin product. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient’s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue. Royalty and Other Revenues Royalties : For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Licenses of intellectual property : If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone payments : At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer. Research and Development R&D costs are generally expensed as incurred. These expenses include contract R&D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&D activities, facilities and regulatory costs and R&D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval. Advance payments for goods or services for use in research and development activities are capitalized and recorded in other current assets, and then expensed as the related goods are delivered or the services are performed. Advertising Expenses The costs of advertising are presented in SG&A in the Consolidated Statements of Operations and are expensed as incurred. Advertising expenses were $27.8 million, $25.2 million and $30.2 million in 2023, 2022 and 2021, respectively. Earnings (Loss) Per Common Share Basic earnings (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted earnings (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive. Stock-Based Compensation The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&D or SG&A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur. Restricted Stock Units The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company’s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model, utilizing expected volatility rates derived from those of the Company and the members of the referenced peer group. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed. Stock Options and Purchase Rights The fair value of each stock option award and purchase rights under the Company’s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is four tranches in a twenty-four-month period. The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company’s stock price and may use assumptions regarding a number of complex and subjective variables. Income Taxes The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances. The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company’s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense. Foreign Currency For the Company and its subsidiaries, the functional currency has been determined to be the U.S. Dollar (USD). Assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates for monetary assets and liabilities. Non-monetary assets and liabilities denominated in foreign currencies are remeasured at historical rates. Foreign currency transaction losses resulting from remeasurement recognized in SG&A in the Consolidated Statements of Operations totaled $27.7 million, $11.4 million and $11.7 million in 2023, 2022 and 2021, respectively. Derivatives and Hedging Activities The Company uses foreign currency exchange forward contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from gross product revenues, operating expenses and monetary asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes. The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements. The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	12 Months Ended
FINANCIAL INSTRUMENTS	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
FINANCIAL INSTRUMENTS	FINANCIAL INSTRUMENTS The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of December 31, 2023 and 2022, respectively: December 31, 2023 Amortized Cost Gross Gross Aggregate Fair Value Cash and Cash Equivalents Short-term Marketable Securities (1) Long-term Marketable Securities (2) Level 1: Cash $ 229,676 $ — $ — $ 229,676 $ 229,676 $ — $ — Level 2: Money market instruments 499,483 — — 499,483 499,483 — — Corporate debt securities 587,896 3,476 (1,996) 589,376 — 193,251 396,125 U.S. government agency securities 251,952 556 (1,140) 251,368 19,976 111,343 120,049 Commercial paper 20,076 5 — 20,081 5,992 14,089 — Asset-backed securities 94,744 351 (134) 94,961 — — 94,961 Subtotal 1,454,151 4,388 (3,270) 1,455,269 525,451 318,683 611,135 Total $ 1,683,827 $ 4,388 $ (3,270) $ 1,684,945 $ 755,127 $ 318,683 $ 611,135 December 31, 2022 Amortized Cost Gross Gross Aggregate Fair Value Cash and Cash Equivalents Short-term Marketable Securities (1) Long-term Marketable Securities (2) Level 1: Cash $ 463,248 $ — $ — $ 463,248 $ 463,248 $ — $ — Level 2: Money market instruments 248,933 — — 248,933 248,933 — — Corporate debt securities 504,984 34 (11,541) 493,477 1,881 299,153 192,443 U.S. government agency securities 312,720 45 (3,771) 308,994 — 229,846 79,148 Commercial paper 48,103 11 (22) 48,092 10,469 37,623 — Asset-backed securities 63,151 69 (592) 62,628 — 384 62,244 Subtotal 1,177,891 159 (15,926) 1,162,124 261,283 567,006 333,835 Total $ 1,641,139 $ 159 $ (15,926) $ 1,625,372 $ 724,531 $ 567,006 $ 333,835 (1) The Company’s short-term marketable securities mature in one year or less. (2) The Company’s long-term marketable securities mature between one As of December 31, 2023, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security’s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss. The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs and remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of December 31, 2023 and December 31, 2022, the fair value of the Company’s strategic investments was $11.3 million and $23.9 million, respectively. These investments were recorded in Other Assets on the Company’s Consolidated Balance Sheets. In 2023, based on new developments, the Company concluded that factors existed indicating it would no longer realize a $12.6 million equity investment in its non-marketable securities. The loss on the equity investment due to impairment was recorded to Other Income (Expense), Net on the Company’s Consolidated Statements of Operations. See Note 1 to these Consolidated Financial Statements for additional discussion regarding the Company’s fair value measurements.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
INTANGIBLE ASSETS	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS Intangible Assets, Net consisted of the following: December 31, 2023 2022 Finite-lived intangible assets $ 710,011 $ 690,871 Accumulated amortization (415,310) (352,302) Net carrying value $ 294,701 $ 338,569 The following table summarizes the carrying value and estimated remaining life of the Company’s finite-lived intangible assets as of December 31, 2023: Net Balance Average Remaining Life Acquired intellectual property $ 185,344 4.4 years Technology transfer 89,221 4.4 years (1) License payments (2) 20,136 9.8 years Total $ 294,701 (1) Certain technology transfer assets have not yet been placed into service. The average remaining life presented is only for those placed into service. (2) License payments include finite-lived intangible assets due to the Company's achievement in 2023 of first commercial sale milestones related to ROCTAVIAN. As of December 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets that have been placed into service, was as follows: Fiscal Year Amount 2024 $ 58,200 2025 38,924 2026 38,924 2027 38,924 2028 23,174 Thereafter 7,293 $ 205,439

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment, Net, consisted of the following: December 31 2023 2022 Building and improvements $ 860,807 $ 819,100 Manufacturing and laboratory equipment 538,677 475,663 Computer hardware and software 211,482 214,829 Land 90,781 90,786 Leasehold improvements 58,230 59,532 Furniture and equipment 46,453 45,762 Land improvements 26,779 26,455 Construction-in-progress (1) 100,013 143,384 1,933,222 1,875,511 Accumulated depreciation (867,089) (802,145) Total property, plant and equipment, net $ 1,066,133 $ 1,073,366 (1) In the fourth quarter of 2023, the Company decided to cease development of the first generation VOXZOGO pen device and impaire d $14.0 million of capitalized tooling and fixed assets that had not been placed in service . Depreciation expense, net of amounts capitalized into inventory, was $40.3 million, $38.6 million and $46.1 million for the years ended December 31, 2023, 2022 and 2021, respectively.

INVENTORY

INVENTORY	12 Months Ended
INVENTORY	Dec. 31, 2023
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY Inventory consisted of the following: December 31 2023 2022 Raw materials $ 155,704 $ 131,071 Work-in-process 571,107 410,656 Finished goods 380,372 352,356 Total inventory $ 1,107,183 $ 894,083

SUPPLEMENTAL FINANCIAL STATEMEN

SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION	12 Months Ended
SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION	SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION Accounts Payable and Accrued Liabilities consisted of the following: December 31, 2023 2022 Accounts payable and accrued operating expenses $ 315,509 $ 231,238 Accrued compensation expense 201,067 207,573 Accrued rebates payable 96,179 72,654 Foreign currency exchange forward contracts 33,853 12,601 Accrued royalties payable 14,299 13,306 Lease liability 8,779 10,375 Accrued income taxes 2,651 16,213 Deferred revenue 4,620 711 Other 6,190 8,288 Total accounts payable and accrued liabilities $ 683,147 $ 572,959 Reorganization Plan Costs On October 6, 2022, the Company announced a plan to simplify its organizational design, which included a planned reduction in headcount. T he Company recorded costs of $23.0 million in 2022 and negligible adjustments in 2023 related to one-time termination severance and employee termination benefits within SG&A expense. As of December 31, 2022 , $11.1 million was include d in Accounts Payable and Accrued Liabilities on the Company’s Consolidated Balance Sheet. As of December 31, 2023 , all accrued costs have been paid. Significant Revenue Rebates and Reserves for Cash Discounts The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December 31, 2023, 2022 and 2021, were as follows: Balance at Beginning of Period Provision for Current Period Sales Payments Balance at End of Period Year ended December 31, 2023: Accrued rebates $ 72,654 $ 196,864 $ (173,339) $ 96,179 Reserve for cash discounts $ 3,639 $ 21,081 $ (19,330) $ 5,390 Year ended December 31, 2022: Accrued rebates $ 47,987 $ 140,260 $ (115,593) $ 72,654 Reserve for cash discounts $ 2,013 $ 20,351 $ (18,725) $ 3,639 Year ended December 31, 2021: Accrued rebates $ 65,526 $ 116,691 $ (134,230) $ 47,987 Reserve for cash discounts $ 1,716 $ 16,003 $ (15,706) $ 2,013

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
FAIR VALUE MEASUREMENTS	Dec. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 1 to these Consolidated Financial Statements. The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December 31, 2023 and 2022. Other than the Company’s fixed-rate convertible debt disclosed in Note 10 to these Consolidated Financial Statements, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December 31, 2023 and 2022. Refer to Notes 2 and 8 to these Consolidated Financial Statements for other financial assets and liabilities measured at fair value. Fair Value Measurements as of December 31, 2023 Significant Other Significant Total Assets: Other current assets: NQDC Plan assets $ 2,026 $ — $ 2,026 Other assets: NQDC Plan assets 28,119 — 28,119 Restricted investments (1) 2,393 — 2,393 Total other assets 30,512 — 30,512 Total assets $ 32,538 $ — $ 32,538 Liabilities: Current liabilities: NQDC Plan liability $ 2,026 $ — $ 2,026 Other long-term liabilities: NQDC Plan liability 28,119 — 28,119 Total liabilities $ 30,145 $ — $ 30,145 Fair Value Measurements as of December 31, 2022 Significant Other Significant Total Assets: Other current assets: NQDC Plan assets $ 2,654 $ — $ 2,654 Other assets: NQDC Plan assets 19,867 — 19,867 Restricted investments (1) 2,429 — 2,429 Total other assets 22,296 — 22,296 Total assets $ 24,950 $ — $ 24,950 Liabilities: Current liabilities: NQDC Plan liability $ 2,654 $ — $ 2,654 Contingent consideration — 15,925 15,925 Total current liabilities 2,654 15,925 18,579 Other long-term liabilities: NQDC Plan liability 19,867 — 19,867 Total other long-term liabilities 19,867 — 19,867 Total liabilities $ 22,521 $ 15,925 $ 38,446 (1) The restricted investments as of December 31, 2023 and 2022 secure the Company’s irrevocable standby letters of credit obtained in connection with certain commercial agreements. There were no transfers between levels during the periods presented. Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration. Contingent consideration as of December 31, 2022 $ 15,925 Milestone payments to Ares Trading S.A. (Merck Serono) (16,255) Realized foreign exchange gain on settlement of contingent consideration 330 Contingent consideration as of December 31, 2023 $ —

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES	12 Months Ended
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES	DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES The Company's forward contracts designated as hedging instruments have maturities up to two years. The Company's forward contracts that are considered to be economic hedges that are not designated as hedging instruments have maturities up to three months. The following table summarizes the aggregate notional amounts for the Company’s derivatives outstanding as of the periods presented. Forward Contracts December 31, 2023 December 31, 2022 Derivatives designated as hedging instruments: Sell $ 1,249,662 $ 808,635 Purchase $ 198,408 $ 177,393 Derivatives not designated as hedging instruments: Sell $ 350,269 $ 218,903 Purchase $ 90,102 $ 6,785 The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows: Balance Sheet Location December 31, 2023 December 31, 2022 Derivatives designated as hedging instruments: Asset Derivatives - Level 2 (1) Other current assets $ 6,663 $ 19,464 Other assets 1,855 2,059 Subtotal $ 8,518 $ 21,523 Liability Derivatives - Level 2 (1) Accounts payable and accrued liabilities $ 30,005 $ 12,130 Other long-term liabilities 8,171 1,074 Subtotal $ 38,176 $ 13,204 Derivatives not designated as hedging instruments: Asset Derivatives - Level 2 (1) Other current assets $ 547 $ 1,472 Liability Derivatives - Level 2 (1) Accounts payable and accrued liabilities $ 3,848 $ 471 Total Derivatives Assets $ 9,065 $ 22,995 Total Derivatives Liabilities $ 42,024 $ 13,675 (1) Refer to Note 1 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements. The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented. Years Ended December 31, 2023 2022 Derivatives Designated as Cash Flow Hedging Instruments Cash Flow Hedging Gains (Losses) Cash Flow Hedging Gains (Losses) Net product revenues $ (186) $ 48,541 Operating expenses $ 350 $ (11,917) Derivatives Not Designated as Hedging Instruments Gains (Losses) Recognized in Earnings Gains (Losses) Recognized in Earnings Operating expenses $ (8,808) $ 872 As of December 31, 2023, the Company expects to reclassify unrealized losses of $23.3 million from AOCI to earnings as the forecasted revenue and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 11 to these Consolidated Financial Statements.

LEASES

LEASES	12 Months Ended
LEASES	Dec. 31, 2023
Leases [Abstract]
LEASES	LEASES The following table presents the Company’s ROU assets and lease liabilities for the periods presented. December 31, Lease Classification Classification 2023 2022 Assets: Operating Other assets $ 42,731 $ 34,935 Financing Other assets 3,343 6,021 Total ROU assets $ 46,074 $ 40,956 Liabilities: Current: Operating Accounts payable and accrued liabilities $ 8,640 $ 8,088 Financing Accounts payable and accrued liabilities 139 2,287 Noncurrent: Operating Other long-term liabilities 38,047 26,329 Financing Other long-term liabilities 77 184 Total lease liabilities $ 46,903 $ 36,888 Maturities of lease liabilities as of December 31, 2023 by fiscal year were as follows: Maturity of Lease Liabilities Operating Financing Total 2024 $ 11,217 $ 142 $ 11,359 2025 9,861 75 9,936 2026 7,966 6 7,972 2027 7,064 — 7,064 2028 6,508 — 6,508 Thereafter 15,811 — 15,811 Total lease payments 58,427 223 58,650 Less: Interest (11,740) (7) (11,747) Present value of lease liabilities $ 46,687 $ 216 $ 46,903 Lease costs associated with payments under the Company’s leases for the periods presented were as follows: Years Ended December 31, Lease Cost Classification 2023 2022 Operating (1) Operating expenses $ 14,197 $ 13,669 Financing: Amortization Operating expenses 3,360 2,858 Interest expense Interest expense 2,648 163 Total lease costs $ 20,205 $ 16,690 (1) Includes short-term leases and variable lease costs, both of which were not material in the periods presented. The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities: Years Ended December 31, Other Information 2023 2022 Weighted average remaining lease term (in years): Operating leases 6.8 5.2 Financing leases 1.6 1.7 Weighted average discount rate: Operating leases 5.9 % 5.1 % Financing leases 3.1 % 5.4 % As of December 31, 2023 , no leases were expected to commence that would create significant rights and obligations for the Company. Years Ended December 31, Supplemental Cash Flow Information 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Cash used in operating activities: Operating leases $ 9,980 $ 10,760 Financing leases $ 51 $ 165 Cash used in financing activities: Financing leases $ 2,286 $ 2,605 ROU assets obtained in exchange for lease obligations: Operating leases $ 16,321 $ 5,252 Financing leases $ 68 $ 878

DEBT

DEBT	12 Months Ended
DEBT	Dec. 31, 2023
Debt Disclosure [Abstract]
DEBT	DEBT Convertible Notes As of December 31, 2023, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt: December 31, 2023 2022 0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes) $ 495,000 $ 495,000 Unamortized discount net of deferred offering costs (1,123) (3,040) 2024 Notes, net (1) 493,877 491,960 1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes) 600,000 600,000 Unamortized discount net of deferred offering costs (6,905) (8,941) 2027 Notes, net 593,095 591,059 Total convertible debt, net $ 1,086,972 $ 1,083,019 Fair value of fixed-rate convertible debt (2) : 2024 Notes $ 488,288 $ 526,230 2027 Notes 619,260 647,370 Total fair value of fixed-rate convertible debt $ 1,107,548 $ 1,173,600 (1) As the 2024 Notes mature in August 2024, the outstanding principal of the 2024 Notes is classified as a current liability as of December 31, 2023. (2) The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note 1 to these Consolidated Financial Statements for additional discussion of fair value measurements. Interest expense on the Company’s fixed-rate convertible debt consisted of the following: Years Ended December 31, 2023 2022 2021 Coupon interest expense $ 10,465 $ 10,465 $ 10,465 Accretion of discount on convertible notes 3,359 3,349 3,339 Amortization of debt issuance costs 594 593 593 Total interest expense on convertible debt $ 14,418 $ 14,407 $ 14,397 2024 Notes In August 2017, the Company issued $495.0 million in aggregate principal amount of senior subordinated convertible notes with a maturity date of August 1, 2024. The 2024 Notes were issued to the public at 98% of face value and bear interest at the rate of 0.599% per annum. Interest is payable semi-annually in cash in arrears on February 1 and August 1 of each year, beginning February 1, 2018. The 2024 Notes are convertible, at the option of the holder into shares of the Company’s common stock. The initial conversion rate for the 2024 Notes is 8.0212 shares per $1,000 principal amount of the 2024 Notes, which represents a conversion price of approximately $124.67 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2024 Notes in connection with such corporate transactions by a number of additional shares of the Company’s common stock. A holder may convert fewer than all of such holder’s 2024 Notes so long as the amount of the 2024 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $481.7 million. In connection with the issuance of the 2024 Notes, the Company recorded a discount on the 2024 Notes of $9.9 million, which will be accreted and recorded as additional interest expense over the life of the 2024 Notes. The 2024 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of any of the Company’s existing and future senior debt, (ii) equal in right of payment to any of the Company’s existing and future senior subordinated debt, (iii) senior in right of payment to any of the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and (iv) effectively subordinated to any of the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness and structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Upon the occurrence of a “fundamental change,” as defined in the indenture governing the 2024 Notes, the holders may require the Company to repurchase all or a portion of such holder’s 2024 Notes for cash at 100% of the principal amount of the 2024 Notes being purchased, plus any accrued and unpaid interest. 2027 Notes In May 2020, the Company issued $600.0 million in aggregate principal amount of senior subordinated unsecured convertible notes with a maturity date of May 15, 2027. The 2027 Notes were issued to the public at par value and bear interest at the rate of 1.25% per annum. Interest is payable semi-annually in cash in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The 2027 Notes are convertible, at the option of the holder into shares of the Company’s common stock. The initial conversion rate for the 2027 Notes is 7.2743 shares per $1,000 principal amount of the 2027 Notes, which represents a conversion price of approximately $137.47 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2027 Notes in connection with such corporate transactions by a number of additional shares of the Company’s common stock. A holder may convert fewer than all of such holder’s 2027 Notes so long as the amount of the 2027 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $585.8 million. In connection with the issuance of the 2027 Notes, the Company recorded a discount on the 2027 Notes of $13.5 million, which will be accreted and recorded as additional interest expense over the life of the 2027 Notes. The 2027 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of all of the Company’s existing and future senior debt, (ii) equal in right of payment with the Company’s existing and future senior subordinated debt, (iii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the notes, (vi) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness, and (v) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Upon the occurrence of a “fundamental change,” as defined in the indenture governing the 2027 Notes, the holders may require the Company to repurchase all or a portion of such holder’s 2027 Notes for cash at 100% of the principal amount of the 2027 Notes being purchased, plus any accrued and unpaid interest. The offer and sale of the 2027 Notes and the shares of the Company’s common stock issuable upon conversion of the 2027 Notes have not been registered under the Securities Act or any state securities laws and the 2027 Notes were offered only to qualified institutional buyers as defined in Rule 144A under the Securities Act. See Note 16 to these Consolidated Financial Statements for further discussion of the effect of conversion of the Company's convertible debt on earnings (loss) per common share. Revolving Credit Facility In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million, which included a letter of credit subfacility and a swingline loan subfacility. The credit facility was intended to finance ongoing working capital needs and for other general corporate purposes. In May 2021, the credit facility was amended to extend the original maturity date from October 19, 2021 to May 28, 2024. The credit facility was terminated on August 4, 2023 and there were no amounts outstanding under the credit facility as of December 31, 2023.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	12 Months Ended
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	Dec. 31, 2023
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented. Unrealized Gains (Losses) on Cash Flow Hedges Unrealized Gains (Losses) on Available-for-Sale Debt Securities Total AOCI balance at December 31, 2020 $ (20,028) $ 3,889 $ (16,139) Other comprehensive income (loss) before 34,379 (6,858) 27,521 Less: gain (loss) reclassified from AOCI (1,454) — (1,454) Tax effect — 1,596 1,596 Net current period other comprehensive income (loss) 35,833 (5,262) 30,571 AOCI balance at December 31, 2021 $ 15,805 $ (1,373) $ 14,432 Other comprehensive income (loss) before 29,045 (13,967) 15,078 Less: gain (loss) reclassified from AOCI 36,624 — 36,624 Tax effect — 3,247 3,247 Net current period other comprehensive income (loss) (7,579) (10,720) (18,299) AOCI balance at December 31, 2022 $ 8,226 $ (12,093) $ (3,867) Other comprehensive income (loss) before (37,720) 16,885 (20,835) Less: gain (loss) reclassified from AOCI 164 — 164 Tax effect — (3,922) (3,922) Net current period other comprehensive income (loss) (37,884) 12,963 (24,921) AOCI balance at December 31, 2023 $ (29,658) $ 870 $ (28,788)

REVENUE, CREDIT CONCENTRATIONS

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION	12 Months Ended
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION	Dec. 31, 2023
Risks and Uncertainties [Abstract]
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION	REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION The following table presents Total Revenues and disaggregates Net Product Revenues by product. Years Ended December 31, 2023 2022 2021 Enzyme product revenues: VIMIZIM $ 701,053 $ 663,739 $ 623,145 NAGLAZYME 420,292 443,794 380,449 PALYNZIQ 303,919 255,032 237,474 BRINEURA 161,889 154,333 128,034 ALDURAZYME 131,248 128,422 122,765 Total enzyme product revenues 1,718,401 1,645,320 1,491,867 VOXZOGO 469,881 169,128 5,855 KUVAN 180,767 227,577 285,776 ROCTAVIAN 3,489 — — Total net product revenues 2,372,538 2,042,025 1,783,498 Royalty and other revenues 46,688 54,014 62,777 Total revenues $ 2,419,226 $ 2,096,039 $ 1,846,275 The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is distributed, marketed and sold exclusively by Sanofi worldwide. Years Ended December 31, 2023 2022 2021 United States $ 771,314 $ 684,284 $ 657,700 Europe 669,331 650,952 558,952 Latin America 332,437 266,801 191,151 Rest of world 468,208 311,566 252,930 Total net product revenues marketed by the Company 2,241,290 1,913,603 1,660,733 ALDURAZYME net product revenues marketed by Sanofi 131,248 128,422 122,765 Total net product revenues $ 2,372,538 $ 2,042,025 $ 1,783,498 The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. Years Ended December 31, 2023 2022 2021 Customer A 14 % 16 % 18 % Customer B 12 % 12 % 14 % Customer C 10 % 9 % 10 % Total 36 % 37 % 42 % On a consolidated basis, two customers accounted for 15% and 12% of the Company’s December 31, 2023 accounts receivable balance, respectively, compared to December 31, 2022 when two customers accounted for 22% and 15% of the accounts receivable balance, respectively. As of December 31, 2023 and 2022, the accounts receivable balance for Sanofi included $63.4 million and $68.8 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances. The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters and supply chain disruptions, could affect the Company’s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business. Long-lived assets, which consist of net property, plant and equipment and ROU assets are summarized by geographic region in the following table. December 31, 2023 2022 Long-lived assets by geography: United States $ 788,590 $ 786,509 Ireland 306,542 309,180 Rest of world 17,075 18,633 Total long-lived assets $ 1,112,207 $ 1,114,322

EQUITY COMPENSATION PLANS AND S

EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION	12 Months Ended
EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION	EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION Equity Compensation Plans Shares Available Under Equity Compensation Plans As of December 31, 2023, an aggregate of approximately 52.3 million unissued shares were authorized for future issuance under the Company’s stock plans, which primarily includes shares issuable under the 2017 Equity Incentive Plan (2017 EIP) and the ESPP. Under the 2017 EIP, shares issued and outstanding under the Amended and Restated 2006 Share Incentive Plan (the 2006 Share Incentive Plan) and the 2017 EIP that expire or are forfeited generally become available for future issuance under the 2017 EIP. No additional awards will be granted under the 2006 Share Incentive Plan; however, there are vested and unvested awards outstanding under the 2006 Share Incentive Plan. The Company’s stock-based compensation plans are administered by the Company’s Board of Directors (the Board), or designated Committee thereof, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the awards. See Note 1 to these Consolidated Financial Statements for discussion regarding the valuation of equity awards. 2017 Equity Incentive Plan The 2017 EIP provides for awards of RSUs and stock options as well as other forms of equity compensation. RSUs granted to employees generally vest annually over a straight-line four-year period after the grant date. RSUs with Performance-based Vesting Conditions (PRSUs) generally vest over a three-year period on a cliff basis three years after the grant date. Stock option awards granted to employees generally vest over a four-year period on a cliff basis 12 months after the grant date and then monthly thereafter. The contractual term of stock option awards is generally 10 years from the grant date. As of December 31, 2023, approximately 39.5 million shares were authorized and reserved for future issuance under the 2017 EIP. Employee Stock Purchase Plan The ESPP was initially approved in June 2006, replacing the Company’s previous plan, and was most recently amended in June 2019. Under BioMarin’s ESPP, employees meeting specific employment qualifications are eligible to participate and can purchase shares on established dates (each purchase date) semi-annually through payroll deductions at the lower of 85% of the fair market value of the stock at the commencement of the offering period or each purchase date of the offering period. Each offering period will span up to two years. The ESPP permits eligible employees to purchase common stock through payroll deductions for up to 10% of qualified compensation, up to an annual limit of $25,000. The ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. During the year ended December 31, 2023, the Company issued 0.3 million shares under the ESPP. As of December 31, 2023, approximately 7.0 million shares were authorized and 2.5 million shares reserved for future issuance under the ESPP. Board of Director Grants On the date of the Company’s annual meeting of stockholders for a given year, each re-elected Independent Director receives an RSU grant valued at $400,000, with the number of RSUs to be granted calculated based on the thirty-day trailing average closing price of the Company’s common stock on the Nasdaq Global Select Market. The annual RSU grant for a director who has served for less than a year is prorated to the nearest quarter of the calendar year. The RSUs subject to the annual award vest in full on the one-year anniversary of the grant date, subject to each respective Director providing service to the Company through such vesting date. Upon election or appointment, a new Independent Director will receive an RSU grant on the same terms as the annual award, pro-rated for amount and vesting to the nearest quarter for the time such new Independent Director will serve prior to the Company’s next annual meeting of stockholders. Stock-based Compensation Stock-based compensation expense included on the Company’s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows: Years Ended December 31, 2023 2022 2021 Cost of sales $ 17,604 $ 17,709 $ 22,357 Research and development 65,714 61,702 67,196 Selling, general and administrative 123,781 116,897 107,710 Total stock-based compensation expense $ 207,099 $ 196,308 $ 197,263 Stock-based compensation of $21.7 million, $21.3 million and $20.0 million was capitalized into inventory for the years ended December 31, 2023, 2022 and 2021, respectively. Capitalized stock-based compensation is recognized in Cost of Sales when the related product is sold. Restricted Stock Units Restricted Stock Unit Awards with Service-Based Vesting Conditions Below is a summary of activity related to RSUs with service-based vesting conditions for the year ended December 31, 2023: Shares Weighted Non-vested units as of December 31, 2022 4,519,746 $ 79.55 Granted 2,150,561 $ 88.96 Vested (1,666,477) $ 80.68 Forfeited (300,005) $ 81.35 Non-vested units as of December 31, 2023 4,703,825 $ 83.39 The weighted-average grant date fair values per share of RSUs with service-based vesting granted during the years ended December 31, 2023, 2022 and 2021, was $88.96, $79.43 and $78.46, respectively. The total intrinsic values of restricted stock that vested and released in the years ended December 31, 2023, 2022 and 2021, was $149.8 million, $130.1 million and $117.2 million respectively. As of December 31, 2023, total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions of $274.7 million was expected to be recognized over a weighted average period of 2.6 years. Restricted Stock Unit Awards with Performance-based Vesting Conditions Below is a summary of activity related to RSUs with vesting conditions based on performance targets for the year ended December 31, 2023: Shares Weighted Average Grant Date Fair Value Non-vested units as of December 31, 2022 447,662 $ 78.78 Granted 230,019 $ 89.22 Vested (231,346) $ 78.30 Forfeited (10,235) $ 78.36 Non-vested units as of December 31, 2023 436,100 $ 83.33 The weighted-average grant date fair value of the PRSUs for the years ended December 31, 2023, 2022 and 2021, was $89.22, $78.27 and $78.09, respectively. Non-vested PRSUs included grants with vesting contingent upon the achievement of three-year performance targets for strategic goals, Non-GAAP income or other internal financial measures and a regulatory milestone. The awarded PRSUs generally vest over a three-year service period on a cliff basis. The Company evaluated the targets in the context of its current long-range financial plan, its product candidate development pipeline and planned regulatory activity to determine when attainment of each grant target was probable for accounting purposes. The number of shares that may be earned range between 50% and 200% of the base PRSUs granted. As of December 31, 2023, total unrecognized compensation expense related to non-vested PRSUs of $10.9 million was expected to be recognized over a weighted average period of 1.3 years. Restricted Stock Unit Awards with Market-based Vesting Conditions The Compensation Committee and Board may grant RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs vest, if at all, in full following a three-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between zero percent and 200% of the base TSR-RSUs with a ceiling achievement level of 100% of the base TSR-RSUs in the event the Company’s TSR is above the 50th percentile but negative on an absolute basis. Below is a summary of activity related to RSUs with market-based vesting conditions for the year ended December 31, 2023: Shares Weighted Average Grant Date Fair Value Non-vested units as of December 31, 2022 396,120 $ 119.61 Granted 261,570 $ 132.56 Vested (248,940) $ 116.05 Forfeited (4,850) $ 121.04 Non-vested units as of December 31, 2023 403,900 $ 128.95 The grant date fair values and assumptions used to determine the fair value of TSR-RSUs on grant date during the periods presented were as follows: Years Ended December 31, 2023 2022 2021 Grant date fair value $132.56 124.67 $117.52 Expected volatility 22.4 – 152.1% 24.5 – 157.6% 24.7 – 161.7% Dividend yield 0.0% 0.0% 0.0% Expected term 2.8 years 2.8 years 2.8 years Risk-free interest rate 3.8% 2.0% 0.3% As of December 31, 2023, total unrecognized compensation expense of $18.0 million related to base TSR-RSUs was expected to be recognized over a weighted average period of 1.4 years. Stock Options and Purchase Rights Stock Options The following table summarizes activity under the Company’s stock option plans for the year ended December 31, 2023. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: Shares Weighted Average Exercise Price Weighted Average Remaining Years Aggregate Intrinsic Value (1) Options outstanding as of December 31, 2022 5,943,535 $ 82.41 $ 132,395 Granted 704,589 $ 89.47 Exercised (837,623) $ 68.82 Expired and forfeited (90,370) $ 82.69 Options outstanding as of December 31, 2023 5,720,131 $ 85.26 5.0 $ 74,704 Options unvested as of December 31, 2023 1,260,219 $ 84.63 8.7 $ 15,139 Exercisable at December 31, 2023 4,459,912 $ 85.44 4.0 $ 59,566 (1) The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $96.42, the closing price of the Company’s common stock on the Nasdaq Global Select Market on December 29, 2023. The weighted-average fair values per stock options granted in the years ended December 31, 2023, 2022 and 2021, were $39.30, $32.45 and $31.61, respectively. The total intrinsic values of options exercised during the years ended December 31, 2023, 2022 and 2021, were $25.9 million, $32.1 million and $40.7 million, respectively, determined as of the date of option exercise. Upon the exercise of the options, the Company issues new common stock from its authorized shares. The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows: Years Ended December 31, 2023 2022 2021 Expected volatility 37.8 – 40.3% 38.1 – 40.5% 39.4 – 41.6% Dividend yield 0.0% 0.0% 0.0% Expected term 4.7 – 6.2 years 4.7 – 6.1 years 4.7 – 6.0 years Risk-free interest rate 3.5 – 4.6% 2.1 – 4.2% 0.7 – 1.3% As of December 31, 2023, total unrecognized compensation cost related to unvested stock options of $36.5 million was expected to be recognized over a weighted average period of 2.7 years. The net tax benefit from stock options exercised during the year ended December 31, 2023 was $2.3 million. Stock Purchase Rights The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows: Years Ended December 31, 2023 2022 2021 Expected volatility 24.0 – 48.0% 28.6 – 69.2% 23.7 – 69.2% Dividend yield 0.0% 0.0% 0.0% Expected term 0.5 – 2.0 years 0.5 – 2.0 years 0.5 – 2.0 years Risk-free interest rate 0.06 – 5.5% 0.04 – 4.8% 0.04 – 2.4% As of December 31, 2023, total unrecognized compensation cost related to unvested stock purchase rights under the ESPP of $14.2 million was expected to be recognized over a weighted average period of 1.4 years.

OTHER EMPLOYEE BENEFITS

OTHER EMPLOYEE BENEFITS	12 Months Ended
OTHER EMPLOYEE BENEFITS	Dec. 31, 2023
Compensation Related Costs [Abstract]
OTHER EMPLOYEE BENEFITS	OTHER EMPLOYEE BENEFITS 401(k) Plan The Company sponsors the BioMarin Retirement Savings Plan (the 401(k) Plan) for eligible U.S. employees. The Company pays the direct expenses of the 401(k) Plan and matches 100% of each participating employee’s eligible contributions, up to a maximum of the lesser of 6% of the employee’s annual compensation or the annual statutory contribution limit. The Company’s matching contribution vests immediately and was approximately $32.7 million, $30.8 million and $31.6 million for the years ended December 31, 2023, 2022 and 2021, respectively. Deferred Compensation Plan The Company maintains the NQDC under which eligible directors and key employees may defer compensation. The NQDC prohibits the diversification of deferrals of Company stock. Company stock issued and held by the NQDC is accounted for similarly to treasury stock in that the fair value of the employer stock was determined on the grant date and the shares are issued into the NQDC when the restricted stock vests. The corresponding deferred compensation obligation is classified as equity with no changes in the fair value of Company stock held in the NQDC recognized in earnings. Other contributions held in the NQDC are classified as trading securities, recorded at fair value with the corresponding deferred compensation obligation classified as a liability and subsequent changes in the fair value of these non-BioMarin investments are recognized in earnings in the period they occur. See Note 7

INCOME TAXES

INCOME TAXES	12 Months Ended
INCOME TAXES	Dec. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Provision for (Benefit from) Income Taxes was based on Income (Loss) before Income Taxes as follows: Years Ended December 31, 2023 2022 2021 U.S. Source $ (453,840) $ (299,403) $ (259,258) Non-U.S. Source 642,403 448,979 183,908 Income (loss) before income taxes $ 188,563 $ 149,576 $ (75,350) The U.S. and foreign components of the Provision for (Benefit from) Income Taxes were as follows: Years Ended December 31, 2023 2022 2021 Provision for (benefit from) income taxes Federal $ 25,120 $ 12,798 $ (2,038) State and local 5,098 5,058 1,339 Foreign 35,681 42,246 5,037 65,899 60,102 4,338 Provision for (benefit from) deferred income taxes: Federal (70,754) (79,270) (29,895) State and local (8,030) (5,143) (1,230) Foreign 33,803 32,326 15,517 (44,981) (52,087) (15,608) Provision for (benefit from) income taxes $ 20,918 $ 8,015 $ (11,270) The following is a reconciliation of the statutory federal income tax benefit to the Company’s effective tax rate: December 31, 2023 2022 2021 Federal statutory income tax rate $ 39,598 $ 31,412 $ (15,824) State and local taxes (3,614) (1,017) 509 Orphan Drug & General Business Credit (39,535) (35,674) (29,363) Stock compensation expense 2,209 6,433 7,859 Foreign Source Income Subject to US Tax 47,721 (5,644) 16,878 Foreign tax rate differential (1) (69,987) (4,051) (16,971) Section 162(m) limitation 9,699 6,577 6,304 Tax Reserves 27,296 18,043 15,530 Intra-entity transfer of assets 5,019 (18,752) (3,920) Valuation allowance/deferred benefit 3,723 7,851 6,821 Other (1,211) 2,837 907 Effective income tax rate $ 20,918 $ 8,015 $ (11,270) (1) For the year ended December 31, 2023, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate. For the year ended December 31, 2022, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and was offset by the income from the sale of a priority review voucher that was taxed at a higher tax rate. For the year ended December 31, 2021, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and includes the recognition of the valuation allowance against a portion of the deferred tax assets of the Company’s Dutch subsidiary of $9.3 million. The significant components of the Company’s net deferred tax assets were as follows: December 31, 2023 2022 Net deferred tax assets: Net operating loss carryforwards $ 19,025 $ 20,657 Tax credit carryforwards 524,652 555,319 Accrued expenses, reserves, and prepaids 107,485 88,697 Intangible assets 789,479 836,402 Capitalized research and development expenses 216,975 103,212 Stock-based compensation 48,744 49,472 Lease liabilities 7,857 5,757 Inventory 18,914 22,726 Other 1,113 5,596 Valuation allowance (119,230) (116,299) Total deferred tax assets 1,615,014 1,571,539 Joint venture basis difference (1,111) (745) Acquired intangibles (1,026) (1,138) ROU Assets (6,917) (5,347) Property, plant and equipment (60,151) (58,897) Total deferred tax liabilities (69,205) (66,127) Net deferred tax assets $ 1,545,809 $ 1,505,412 The increase in net deferred tax assets is primarily related to capitalization of research and development expenses offset by a decrease in intangible assets and tax credits utilized. Valuation allowances are provided to reduce the amounts of the Company's deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense. In the third quarter of 2023, the Company determined that it is more likely than not that the deferred tax assets related to a future royalty stream will be realized. In making this determination, the Company analyzed both the consistent historical royalty earnings and the forecast of future royalty earnings and reached the conclusion that it was appropriate to release the valuation allowance reserve. The release is offset by an increase due to the Company’s expectation that state R&D credits generated will not be utilized. As of December 31, 2023, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows: Type Amount Year Federal net operating loss carryforwards $ 3,296 2030-2033 Federal R&D and orphan drug credit carryforwards $ 555,074 2024-2043 State net operating loss carryforwards $ 208,592 2024-2043 Dutch net operating loss carryforwards $ 31,361 Indefinite Not included in the table above are $169.6 million of state research credit carryovers that will carry forward indefinitely. The Company’s net operating losses and credits could be subject to annual limitations due to ownership change limitations provided by Internal Revenue Code Section 382 and similar state provisions. An annual limitation could result in the expiration of net operating losses and tax credit carryforward before utilization. There are limitations on the tax attributes of acquired entities however, the Company does not believe the limitations will have a material impact on the utilization of the net operating losses or tax credits. The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December 31, 2023 and 2022, is as follows: December 31, 2023 2022 Balance at beginning of period $ 232,856 $ 205,095 Additions based on tax positions related to the current year 41,473 26,762 Additions for tax positions of prior years 3,127 1,017 Lapse of statute of limitations — (18) Balance at end of period $ 277,456 $ 232,856 Included in the balance of unrecognized tax benefits as of December 31, 2023 were potential benefits of $266.5 million that, if recognized, would affect the effective tax rate. The Company’s policy for classifying interest and penalties associated with unrecognized income tax benefits is to include such items in the income tax expense. The total amount of accrued interest and penalties was not significant as of December 31, 2023. The Company believes it will not have any material decreases in its previously unrecognized tax benefits within the next twelve months. The Company files income tax returns in the U.S., Ireland and various foreign jurisdictions. The U.S. and foreign jurisdictions have statute of limitations ranging from three U.S. income and foreign withholding taxes have not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration. This excess totaled approximately $15.1 million as of December 31, 2023, which will be indefinitely reinvested; deferred income taxes have not been provided on such foreign earnings.

EARNINGS (LOSS) PER COMMON SHAR

EARNINGS (LOSS) PER COMMON SHARE	12 Months Ended
EARNINGS (LOSS) PER COMMON SHARE	Dec. 31, 2023
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER COMMON SHARE	EARNINGS (LOSS) PER COMMON SHARE Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company’s ESPP, unvested RSUs and contingent issuances of common stock related to the Company's convertible debt. The following table sets forth the computation of basic and diluted earnings (loss) per common share (common shares in thousands): Twelve Months Ended 2023 2022 2021 Numerator: Net income (loss) $ 167,645 $ 141,561 $ (64,080) Denominator: Weighted-average common shares outstanding, basic 187,834 185,266 182,852 Effect of dilutive securities: Common stock issuable under the Company's equity incentive plans 3,761 3,697 — Weighted-average common shares outstanding, diluted 191,595 188,963 182,852 Earnings (loss) per common share, basic $ 0.89 $ 0.76 $ (0.35) Earnings (loss) per common share, diluted $ 0.87 $ 0.75 $ (0.35) In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings (loss) per common share as they were anti-dilutive (in thousands): Twelve Months Ended 2023 2022 2021 Common stock issuable under the Company's equity incentive plans 8,072 8,148 12,450 Common stock issuable under the Company’s convertible debt (1) 8,335 8,335 8,335 Total number of potentially issuable shares 16,407 16,483 20,785 (1) If converted, the Company would issue 4.0 million shares under the 2024 Notes and 4.4 million shares under the 2027 Notes. For additional discussion of our convertible debt, see Note 10

LICENSE AND COLLABORATION AGREE

LICENSE AND COLLABORATION AGREEMENTS	12 Months Ended
LICENSE AND COLLABORATION AGREEMENTS	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LICENSE AND COLLABORATION AGREEMENTS	LICENSE AND COLLABORATION AGREEMENTS In October 2019, the Company entered into a worldwide, exclusive licensing agreement with a third party for tralesinidase alfa (formerly referred to as BMN 250), an investigational enzyme replacement therapy to treat Sanfilippo Syndrome Type B. In consideration, the Company received an upfront payment of $3.0 million, a minority 15% equity ownership interest in the licensee, and is entitled to receive royalties on net sales of tralesinidase alfa and milestone payments if certain development, regulatory and sales milestones are met by the licensee. Subsequently, the third party licensee raised additional funding and issued the Company incremental shares to maintain its 15% minority interest. As of December 31, 2022, the balance of the equity investment included in Other Assets on the Company’s Consolidated Balance Sheets was $12.6 million, which was fully impaired in 2023 based on new developments that lead the Company to conclude that factors existed indicating this non-marketable strategic investment was no longer realizable. The loss on the equity investment due to impairment was recorded to Other Income (Expense), Net on the Company’s Consolidated Statements of Operations. In July 2017, the Company executed a license agreement with Sarepta Therapeutics (Sarepta) that provides Sarepta with global exclusive rights to the Company’s Duchenne muscular dystrophy (DMD) patent estate for EXONDYS 51 and all future exon-skipping products. Under the license agreement, Sarepta pays the Company royalties and may pay the Company certain milestone payments for exons 51, 45, 53 and possibly other exon-skipping products. In 2021, the Company and Sarepta amended the license agreement to, among other things, make the license co-exclusive at a future date and reduce future royalty rates. On October 1, 2015, the Company entered into an agreement with Ares Trading S.A. (Merck Serono) under which the Company acquired all global rights to KUVAN and PALYNZIQ from Merck Serono, with the exception of KUVAN in Japan. Previously, the Company had exclusive rights to KUVAN in the U.S. and Canada and PALYNZIQ in the U.S. and Japan. Pursuant to the amended and restated KUVAN Agreement, if future sales milestones were met, the Company was obligated to pay Merck Serono up to a maximum of €60.0 million, all of which were met and paid as of December 31, 2023. Pursuant to the Pegvaliase Agreement, the Company also paid Merck Serono €125.0 million in cash when the PALYNZIQ development milestones were achieved. In October 2012, the Company licensed to Catalyst Pharmaceutical Partners, Inc. (Catalyst) the North American rights to develop and market FIRDAPSE, the Company's former commercial product for the treatment of Lambert-Eaton myasthenic syndrome. In exchange for the North American rights to FIRDAPSE, commencing in the first quarter of 2019 the Company receives royalties of 7% to 10% on net product sales of FIRDAPSE in North America. The Company is engaged in R&D collaborations with various other entities. These provide for sponsorship of R&D by the Company and may also provide for exclusive royalty-bearing intellectual property licenses or rights of first negotiation regarding licenses to intellectual property development under the collaborations. Typically, these agreements can be terminated for cause by either party upon written notice. In 2020, the Company entered into a research and collaboration agreement with a third party and received a convertible note, which was recorded in Other Assets on the Company's Consolidated Balance Sheets. In 2023, the Company recorded a $11.9 million impairment loss on the convertible note as it was deemed unrecoverable based on new information. The impairment loss was recorded to Other Income (Expense), Net on the Company's Consolidated Statements of Operations.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Contingencies From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable based on existing information. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. Liabilities are evaluated and refined each reporting period as additional information is known. Any receivables for insurance recoveries for these liability claims are recorded as assets when it is probable that a recovery will be realized. The Company was involved in a purported shareholder class action lawsuit filed against the Company and certain officers and directors alleging violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 as amended (the Exchange Act) for making materially false or misleading statements regarding the clinical trials and Biologics License Application (BLA) for ROCTAVIAN (formerly known as valoctocogene roxaparvovec) by purportedly failing to disclose that differences between the Company’s Phase 1/2 and Phase 3 clinical studies limited the ability of the Phase 1/2 study to support ROCTAVIAN’s durability of effect and, as a result, that it was foreseeable that the FDA would not approve the BLA without additional data. On March 21, 2023, the Court entered an order staying all proceedings and vacating all deadlines because the parties agreed to settle the case through a binding term sheet. The Court preliminarily approved the settlement on June 8, 2023. On November 14, 2023, the court granted final approval of the settlement and entered final judgment. The Company maintains directors and officers liability insurance that covers exposure related to this class action lawsuit. As of December 31, 2022, the Company had recorded an estimated long-term loss contingency of $13.0 million on the Company’s Consolidated Balance Sheets. The same amount was recorded for expected insurance recoveries. During 2023, the amount recorded on the Company's Consolidated Balance Sheets increased to $39.0 million based on the final settlement and was reclassified to short term. As of December 31, 2023, the $39.0 million settlement liability and related receivable have been released following the final judgment. There was a net zero impact on the Company's Consolidated Statements of Cash Flows and Consolidated Statement of Operations in the years presented. The Company recently received a subpoena from the U.S. Department of Justice (DOJ) requesting that the Company produce certain documents regarding sponsored testing programs relating to VIMIZIM and NAGLAZYME. The Company has produced the requested documents in response to the subpoena and is cooperating fully. The Company is unable to make any assurances regarding the outcome of the investigation by the DOJ, or the impact, if any, that such investigation may have on the Company’s business, Consolidated Balance Sheets, Statements of Operations or Statements of Cash Flows. Contingent Payments As of December 31, 2023, the Company was subject to contingent payments, primarily comprised of development, regulatory and commercial milestones. Those considered reasonably possible totaled $763.3 million, of this amount the Company may pay up to $30.1 million in 2024 if certain contingencies are met. $591.5 million of the total balance related to early-stage development programs licensed from two third parties. Other Commitments The Company uses experts and laboratories at universities and other institutions to perform certain R&D activities. These amounts are included as R&D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&D services, production services and facility construction services. The Company also has commitments related to enterprise resource planning system implementation costs. As of December 31, 2023, such commitments were estimated at $354.1 million, of which $325.9 million is expected to be paid in 2024 as underlying goods and services are received. The Company has also licensed technology from third parties, for which it is required to pay royalties upon future sales, subject to certain annual minimums.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Pay vs Performance Disclosure
Net income (loss)	$ 167,645	$ 141,561	$ (64,080)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2023 shares	Dec. 31, 2023 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false
Erin Burkhart [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		During the three months ended December 31, 2023, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities set forth in the table below. Type of Trading Arrangement Name Position Action Adoption/Termination Rule 10b5-1 (1) Non- Rule 10b5-1 (2) Total Shares of Common Stock to be Sold (3) Expiration Date Erin Burkhart Group Vice President and Chief Accounting Officer Termination November 29, 2023 X up to 2,782 March 8, 2024 Erin Burkhart Group Vice President and Chief Accounting Officer Adoption November 29, 2023 X up to 5,709 November 29, 2024 (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan.
Erin Burkhart Plan One [Member] \| Erin Burkhart [Member]
Trading Arrangements, by Individual
Name	Erin Burkhart
Title	Group Vice President and Chief Accounting Officer
Rule 10b5-1 Arrangement Terminated	true
Termination Date	November 29, 2023
Aggregate Available	2,782	2,782
Erin Burkhart Plan Two [Member] \| Erin Burkhart [Member]
Trading Arrangements, by Individual
Name	Erin Burkhart
Title	Group Vice President and Chief Accounting Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	November 29, 2023
Arrangement Duration	366 days
Aggregate Available	5,709	5,709

BUSINESS OVERVIEW AND SIGNIFI_2

BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Management performed an evaluation of the Company’s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing of this Annual Report on Form 10-K.
Use of Estimates	Use of Estimates U.S. GAAP requires management to make estimates and assumptions that affect amounts reported on the Company’s Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results.
Cash and Cash Equivalents	Cash and Cash Equivalents
Marketable Securities	Marketable Securities The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designations at each reporting period. The Company classifies its debt and equity securities with original maturities greater than three months when purchased as either short-term or long-term investments based on each instrument’s underlying contractual maturity date and its availability for use in current operations. All marketable securities are classified as available-for-sale. Available-for-sale debt securities are measured and recorded at fair market value with unrealized gains and losses included in Accumulated Other Comprehensive Income (AOCI) on the Company’s Consolidated Balance Sheets, with the exception of any declines in fair value below the cost basis that are a result of a credit loss, which, if any, are reported in Other Income (Expense), Net in the current period through an allowance for credit losses. Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if so, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date.
Non-Marketable Equity Securities	Non-Marketable Equity Securities The Company records investments in equity securities, other than equity method investments, at fair market value, if fair value is readily determinable. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost adjusted for observable price changes in orderly transactions for identical or similar investments of the same
Inventory	Inventory Commercial Inventory The Company values inventory at the lower of cost and net realizable value and determines the cost of inventory using the average-cost approach on the first-in, first out (FIFO) method. The Company analyzes its inventory levels quarterly for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as Cost of Sales in the Consolidated Statements of Operations. Inventory Produced Prior to Regulatory Approval When future commercialization for a product candidate is considered probable and management believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced and the Company expects to realize economic benefit in the future, the Company capitalizes pre-launch or pre-qualification manufacturing costs prior to regulatory approval. For inventories that are capitalized in preparation of product launch, a number of factors are taken into consideration based on information available at the time, including the product candidate’s current status in the drug development and regulatory approval process, results from the related pivotal clinical trial, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and market trends. If additional requirements are subsequently presented by the regulatory authorities, prior to their final decision thus extending anticipated regulatory approval timelines resulting in expiration of the product prior to revised demand forecasts, the pre-launch inventory costs are expensed to Cost of Sales. If the marketing application is ultimately rejected by the applicable regulators and the pre-launch inventory cannot be sold for commercial use, the pre-launch inventory costs are expensed to Research and Development (R&D).
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at historical cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the related estimated useful lives, as presented in the table below. Significant additions and improvements are capitalized, whereas repairs and maintenance are expensed as incurred. Depreciation of property, plant and equipment are included in Cost of Sales, R&D and Selling, General and Administrative (SG&A), as appropriate, in the Consolidated Statements of Operations. Property and equipment purchased for specific R&D projects with no alternative future uses are expensed as incurred and recorded to R&D in the Consolidated Statements of Operations. Leasehold improvements Shorter of life of asset or lease term Building and improvements 20 to 50 years Manufacturing and laboratory equipment 5 to 15 years Computer hardware and software 3 to 7 years Office furniture and equipment 5 years Land improvements 10 to 20 years Land Not applicable Construction-in-progress Not applicable
Leases	Leases The Company's lease portfolio primarily consists of leases for properties and equipment for administrative, manufacturing and R&D activities. The Company determines if an arrangement is a lease at contract inception. For leases where the Company is the lessee, Right of Use (ROU) assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent the lease payment obligation. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and are not included in the recognized ROU assets and lease liabilities.
Goodwill and Intangible Assets	Goodwill and Intangible Assets The Company records goodwill in a business combination when the total consideration exceeds the fair value of the assets acquired. Intangible assets with indefinite useful lives are related to purchased in-process research and development (IPR&D) projects and are measured at their respective fair values as of the acquisition date. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets are considered finite-lived and are amortized using the straight-line method based on their respective estimated useful lives at that point in time. The amortization of these intangible assets is included in Intangible Asset Amortization and Contingent Consideration in the Consolidated Statements of Operations. Intangible assets with finite useful lives primarily consist of acquired intellectual property and royalty rights, regulatory approval and first commercial sales milestone payments as well as costs associated with technology transfer to qualify third-party manufacturing facilities for commercial production. Intangible assets are recorded at cost, net of accumulated amortization, and amortize over their estimated useful lives on a straight-line basis. Amortization expense is recorded in Intangible Asset Amortization and Contingent Consideration on the Company's Consolidated Statements of Operations, except for amortization expense related to the technology transfer, which is recorded in Cost of Sales.
Impairment and Long-lived Asset Impairment	Impairment The Company assesses goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter, or more frequently as warranted by events or changes in circumstances that indicate that the carrying amount may not be recoverable. Goodwill is assessed for impairment by comparing the fair value of the Company’s reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, an impairment loss equal to the difference would be recorded. Indefinite-lived intangible assets are assessed for impairment first by performing a qualitative assessment. If the qualitative assessment indicates that it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, then the Company will perform a quantitative assessment and record an impairment loss. Long-lived Asset Impairment
Capitalized Software	Capitalized Software
Revenue Recognition	Revenue Recognition The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. Net Product Revenues In the U.S., the Company’s commercial products, except for PALYNZIQ and ALDURAZYME, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. PALYNZIQ is distributed in the U.S. through certain certified specialty pharmacies under the PALYNZIQ Risk Evaluation and Mitigation Strategy (REMS) and ALDURAZYME is marketed world-wide by Sanofi. Outside the U.S., the Company’s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment to the customer. The Company's payment terms vary by customer, jurisdiction or, in some instances, by product. With the exception of Sanofi and certain outcomes-based contracts, most of the Company's payment terms are based on customary commercial terms and are generally less than one year after the customer obtains control. The Company does not adjust revenue for the effects of a significant financing component for contracts if the period between the transfer of control and corresponding payment is expected to be one year or less. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis on the Company’s Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of Net Product Revenues. For ALDURAZYME revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net ALDURAZYME sales by Sanofi depending on sales volume, which is included in Net Product Revenues on the Company’s Consolidated Statements of Operations. The Company recognizes its best estimate of the revenue it expects to earn when the product is released and control is transferred to Sanofi. The Company records ALDURAZYME net product revenues based on the estimated variable consideration payable when the product is sold through by Sanofi. Actual amounts of consideration ultimately received may differ from the Company’s estimates. Differences between the estimated variable consideration to be received from Sanofi and actual payments received are not expected to be material. If actual results vary from the Company’s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known. Revenue Reserves Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from government and commercial rebates, chargebacks, sales returns, and other incentives that are offered within contracts between the Company and its customers, such as specialty pharmacies, hospitals, authorized distributors and government purchasers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, patient outcomes, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates, however the Company does not expect any such difference to be material. If actual results in the future vary from the Company’s estimates, the Company will adjust its estimates, which would affect net product revenue and earnings in the period such variances become known. Government and Commercial Rebates : The Company records reserves for rebates payable under government programs, such as Medicaid, and commercial arrangements, such as managed care rebates, as a reduction of revenue at the time product revenues are recorded. The Company’s reserve calculations require estimates, including estimates of customer mix and patient outcomes, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions on a quarterly basis and records any necessary adjustments to its reserves. Sales Returns : The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers’ limited return rights and the Company’s historical experience with returns. Because of the pricing of the Company’s commercial products, the limited number of patients and the customers’ limited return rights, most customers and retailers carry a limited inventory. The Company relies on historical return rates to estimate a reserve for returns. Based on these factors and the fact that the Company has not experienced significant product returns to date, return allowances are not material. Other Incentives : Other incentives include fees paid to the Company’s distributors and discounts for prompt payment. The Company also offers a branded co-pay assistance program for eligible patients with commercial insurance in the U.S. who are on an eligible BioMarin product. The branded co-pay assistance programs assist commercially insured patients who have coverage for an eligible BioMarin product and are intended to reduce each participating patient’s portion of the financial responsibility of the purchase price up to a specified dollar amount of assistance. The Company records fees paid to distributors, cash discounts and amounts paid under the brand specific co-pay assistance program for each patient as a reduction of revenue. Royalty and Other Revenues Royalties : For arrangements that include the receipt of sales-based royalties, including milestone payments based on the level of sales when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Licenses of intellectual property : If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone payments : At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates whether achieving the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.
Research and Development	Research and Development R&D costs are generally expensed as incurred. These expenses include contract R&D services provided by third parties, preclinical and clinical studies, raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&D activities, facilities and regulatory costs and R&D-related personnel costs including salaries, benefits and stock-based compensation. Upfront and milestone payments made to third parties in connection with licensed intellectual property, which does not have an alternative future use or does not reach technological feasibility, are expensed as incurred up to the point of regulatory approval. Advance payments for goods or services for use in research and development activities are capitalized and recorded in other current assets, and then expensed as the related goods are delivered or the services are performed.
Advertising Expenses	Advertising Expenses
Earnings (Loss) Per Common Share	Earnings (Loss) Per Common Share Basic earnings (loss) per share is calculated by dividing Net Income (Loss) by the weighted average shares of common stock outstanding during the period. Diluted earnings (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive.
Stock-Based Compensation	Stock-Based Compensation The Company has equity incentive plans under which various types of equity-based awards may be granted to employees. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting, and is classified as Cost of Sales, R&D or SG&A, as appropriate, in the Consolidated Statements of Operations. The Company accounts for forfeitures as they occur. Restricted Stock Units The fair value of restricted stock units (RSUs) with service-based vesting conditions and RSUs with performance conditions is determined to be the fair market value of the Company’s underlying common stock on the date of grant. The stock-based compensation expense for RSUs with service-based vesting is recognized over the period during which the vesting restrictions lapse. Stock-based compensation expense for RSUs with performance conditions is recognized beginning in the period the Company determines it is probable that the performance condition will be achieved. Management expectations related to the achievement of performance goals associated with RSUs with performance conditions are assessed regularly to determine whether such grants are expected to vest. The fair value for RSUs with market conditions is estimated using the Monte Carlo valuation model, utilizing expected volatility rates derived from those of the Company and the members of the referenced peer group. Related stock-based compensation is recognized, beginning on the grant date, on a straight-line basis regardless of whether the market condition is met unless the required service is not performed. Stock Options and Purchase Rights The fair value of each stock option award and purchase rights under the Company’s Employee Stock Purchase Plan (ESPP) are estimated on the date of grant using the Black-Scholes valuation model and the following assumptions: expected term, expected volatility, risk-free interest rate and expected dividend yield. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The expected term of stock options is based on observed historical exercise patterns. In estimating the life of stock options, the Company has identified two employee groups with distinctly different historical exercise patterns: executive and non-executive. The executive employee group has a history of holding stock options for longer periods than non-executive employees. The expected term of purchase rights for ESPP is based on each tranche of an offering period, which is four tranches in a twenty-four-month period. The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company’s stock price and may use assumptions regarding a number of complex and subjective variables.
Income Taxes	Income Taxes The Company calculates and provides for income taxes in each of the tax jurisdictions in which it operates. Deferred tax assets and liabilities, measured using enacted tax rates, are recognized for the future tax consequences of temporary differences between the tax and financial statement basis of assets and liabilities. A valuation allowance reduces the deferred tax assets to the amount that is more likely than not to be realized. The Company establishes liabilities or reduces assets for uncertain tax positions when the Company believes certain tax positions are not more likely than not of being sustained if challenged. Each quarter, the Company evaluates these uncertain tax positions and adjusts the related tax assets and liabilities in light of changing facts and circumstances. The Company uses financial projections to support its net deferred tax assets, which contain significant assumptions and estimates of future operations. If such assumptions were to differ significantly, it may have a material impact on the Company’s ability to realize its deferred tax assets. At the end of each period, the Company will reassess the ability to realize its deferred tax benefits. If it is more likely than not that the Company would not realize the deferred tax benefits, a valuation allowance may need to be established against all or a portion of the deferred tax assets, which will result in a charge to tax expense.
Foreign Currency	Foreign Currency
Derivatives and Hedging Activities	Derivatives and Hedging Activities The Company uses foreign currency exchange forward contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted revenues and operating expenses being denominated in currencies other than the USD, primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from gross product revenues, operating expenses and monetary asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes. The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements. The Company accounts for its derivative instruments as either assets or liabilities on its Consolidated Balance Sheets and measures them at fair value, which is estimated using current exchange and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in AOCI and amounts deferred in AOCI are reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in SG&A in the Consolidated Statements of Operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use the following techniques: • Income approach, which is based on the present value of a future stream of net cash flows • Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities. The Company’s fair value methodologies depend on the following types of inputs: • Quoted prices for identical assets or liabilities in active markets (Level 1 inputs) • Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities that are not active, or inputs other than quoted process that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs) • Unobservable inputs that reflect estimates and assumptions (Level 3 inputs) The Company’s Level 2 instruments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets. The Company’s Level 3 financial assets and liabilities include acquired intangible assets and contingent consideration resulting from business acquisitions. The estimated fair value of acquired finite-lived and indefinite-lived intangible assets and contingent consideration are measured by applying a probability-based income approach utilizing an appropriate discount rate as of the acquisition date. Key assumptions used by management to estimate the fair value of contingent consideration include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Changes in the fair value of contingent consideration can result from changes to one or more inputs, including the estimated probability with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Contingent consideration is remeasured on a recurring basis and resulting changes in the fair value, due to the revision of key assumptions, are recorded in Intangible Asset Amortization and Contingent Consideration on the Company’s Consolidated Statements of Operations. See Notes 2 , 7 , 8 , and 10 to these Consolidated Financial Statements for further information on the nature of these financial instruments.
Segment Information	Segment Information The Company currently operates in one segment focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. All products are included in one operating segment because the majority of the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company is not organized by market and is managed and operated as one business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate products, other than revenues, cost of sales and certain other operating expenses.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There have been no new accounting pronouncements adopted by the Company during 2023. The following paragraphs discuss new accounting pronouncements issued by the Financial Accounting Standards Board (FASB), but not yet adopted by the Company. Segment Reporting In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, Segment Reporting Topic 280, Improvements to Reportable Segment Disclosures , to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segment’s profit or loss and assets. The effective date for the update is for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 and should be applied on a retrospective basis to all periods presented. The Company is currently evaluating the effect of adopting the update on the Company's disclosures. Income Taxes In December 2023, the FASB issued ASU 2023-09, Income Taxes Topic 740, Improvements to Income Tax Disclosures . The guidance requires disclosure of disaggregated information about the Company’s effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it

BUSINESS OVERVIEW AND SIGNIFI_3

BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Property, Plant and Equipment Estimated Useful Lives	Leasehold improvements Shorter of life of asset or lease term Building and improvements 20 to 50 years Manufacturing and laboratory equipment 5 to 15 years Computer hardware and software 3 to 7 years Office furniture and equipment 5 years Land improvements 10 to 20 years Land Not applicable Construction-in-progress Not applicable

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
FINANCIAL INSTRUMENTS (Tables)	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of Cash Cash Equivalents and Available-for-Sale Securities by Significant Investment Category	The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of December 31, 2023 and 2022, respectively: December 31, 2023 Amortized Cost Gross Gross Aggregate Fair Value Cash and Cash Equivalents Short-term Marketable Securities (1) Long-term Marketable Securities (2) Level 1: Cash $ 229,676 $ — $ — $ 229,676 $ 229,676 $ — $ — Level 2: Money market instruments 499,483 — — 499,483 499,483 — — Corporate debt securities 587,896 3,476 (1,996) 589,376 — 193,251 396,125 U.S. government agency securities 251,952 556 (1,140) 251,368 19,976 111,343 120,049 Commercial paper 20,076 5 — 20,081 5,992 14,089 — Asset-backed securities 94,744 351 (134) 94,961 — — 94,961 Subtotal 1,454,151 4,388 (3,270) 1,455,269 525,451 318,683 611,135 Total $ 1,683,827 $ 4,388 $ (3,270) $ 1,684,945 $ 755,127 $ 318,683 $ 611,135 December 31, 2022 Amortized Cost Gross Gross Aggregate Fair Value Cash and Cash Equivalents Short-term Marketable Securities (1) Long-term Marketable Securities (2) Level 1: Cash $ 463,248 $ — $ — $ 463,248 $ 463,248 $ — $ — Level 2: Money market instruments 248,933 — — 248,933 248,933 — — Corporate debt securities 504,984 34 (11,541) 493,477 1,881 299,153 192,443 U.S. government agency securities 312,720 45 (3,771) 308,994 — 229,846 79,148 Commercial paper 48,103 11 (22) 48,092 10,469 37,623 — Asset-backed securities 63,151 69 (592) 62,628 — 384 62,244 Subtotal 1,177,891 159 (15,926) 1,162,124 261,283 567,006 333,835 Total $ 1,641,139 $ 159 $ (15,926) $ 1,625,372 $ 724,531 $ 567,006 $ 333,835 (1) The Company’s short-term marketable securities mature in one year or less. (2) The Company’s long-term marketable securities mature between one

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
INTANGIBLE ASSETS (Tables)	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Net	Intangible Assets, Net consisted of the following: December 31, 2023 2022 Finite-lived intangible assets $ 710,011 $ 690,871 Accumulated amortization (415,310) (352,302) Net carrying value $ 294,701 $ 338,569
Schedule of Carrying Value and Estimated Remaining Life of Finite-Lived Intangible Assets	The following table summarizes the carrying value and estimated remaining life of the Company’s finite-lived intangible assets as of December 31, 2023: Net Balance Average Remaining Life Acquired intellectual property $ 185,344 4.4 years Technology transfer 89,221 4.4 years (1) License payments (2) 20,136 9.8 years Total $ 294,701 (1) Certain technology transfer assets have not yet been placed into service. The average remaining life presented is only for those placed into service. (2) License payments include finite-lived intangible assets due to the Company's achievement in 2023 of first commercial sale milestones related to ROCTAVIAN.
Schedule of Estimated Future Amortization Expense	As of December 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets that have been placed into service, was as follows: Fiscal Year Amount 2024 $ 58,200 2025 38,924 2026 38,924 2027 38,924 2028 23,174 Thereafter 7,293 $ 205,439

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT (Tables)	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	Property, Plant and Equipment, Net, consisted of the following: December 31 2023 2022 Building and improvements $ 860,807 $ 819,100 Manufacturing and laboratory equipment 538,677 475,663 Computer hardware and software 211,482 214,829 Land 90,781 90,786 Leasehold improvements 58,230 59,532 Furniture and equipment 46,453 45,762 Land improvements 26,779 26,455 Construction-in-progress (1) 100,013 143,384 1,933,222 1,875,511 Accumulated depreciation (867,089) (802,145) Total property, plant and equipment, net $ 1,066,133 $ 1,073,366 (1) In the fourth quarter of 2023, the Company decided to cease development of the first generation VOXZOGO pen device and impaire d $14.0 million of capitalized tooling and fixed assets that had not been placed in service .

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
INVENTORY (Tables)	Dec. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following: December 31 2023 2022 Raw materials $ 155,704 $ 131,071 Work-in-process 571,107 410,656 Finished goods 380,372 352,356 Total inventory $ 1,107,183 $ 894,083

SUPPLEMENTAL FINANCIAL STATEM_2

SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION (Tables)	12 Months Ended
SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION (Tables)	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accounts Payable and Accrued Liabilities consisted of the following: December 31, 2023 2022 Accounts payable and accrued operating expenses $ 315,509 $ 231,238 Accrued compensation expense 201,067 207,573 Accrued rebates payable 96,179 72,654 Foreign currency exchange forward contracts 33,853 12,601 Accrued royalties payable 14,299 13,306 Lease liability 8,779 10,375 Accrued income taxes 2,651 16,213 Deferred revenue 4,620 711 Other 6,190 8,288 Total accounts payable and accrued liabilities $ 683,147 $ 572,959
Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts	The roll forward of significant estimated accrued rebates and reserve for cash discounts for the years ended December 31, 2023, 2022 and 2021, were as follows: Balance at Beginning of Period Provision for Current Period Sales Payments Balance at End of Period Year ended December 31, 2023: Accrued rebates $ 72,654 $ 196,864 $ (173,339) $ 96,179 Reserve for cash discounts $ 3,639 $ 21,081 $ (19,330) $ 5,390 Year ended December 31, 2022: Accrued rebates $ 47,987 $ 140,260 $ (115,593) $ 72,654 Reserve for cash discounts $ 2,013 $ 20,351 $ (18,725) $ 3,639 Year ended December 31, 2021: Accrued rebates $ 65,526 $ 116,691 $ (134,230) $ 47,987 Reserve for cash discounts $ 1,716 $ 16,003 $ (15,706) $ 2,013

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value	The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Consolidated Financial Statements that are remeasured on a recurring basis as of December 31, 2023 and 2022. Other than the Company’s fixed-rate convertible debt disclosed in Note 10 to these Consolidated Financial Statements, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of December 31, 2023 and 2022. Refer to Notes 2 and 8 to these Consolidated Financial Statements for other financial assets and liabilities measured at fair value. Fair Value Measurements as of December 31, 2023 Significant Other Significant Total Assets: Other current assets: NQDC Plan assets $ 2,026 $ — $ 2,026 Other assets: NQDC Plan assets 28,119 — 28,119 Restricted investments (1) 2,393 — 2,393 Total other assets 30,512 — 30,512 Total assets $ 32,538 $ — $ 32,538 Liabilities: Current liabilities: NQDC Plan liability $ 2,026 $ — $ 2,026 Other long-term liabilities: NQDC Plan liability 28,119 — 28,119 Total liabilities $ 30,145 $ — $ 30,145 Fair Value Measurements as of December 31, 2022 Significant Other Significant Total Assets: Other current assets: NQDC Plan assets $ 2,654 $ — $ 2,654 Other assets: NQDC Plan assets 19,867 — 19,867 Restricted investments (1) 2,429 — 2,429 Total other assets 22,296 — 22,296 Total assets $ 24,950 $ — $ 24,950 Liabilities: Current liabilities: NQDC Plan liability $ 2,654 $ — $ 2,654 Contingent consideration — 15,925 15,925 Total current liabilities 2,654 15,925 18,579 Other long-term liabilities: NQDC Plan liability 19,867 — 19,867 Total other long-term liabilities 19,867 — 19,867 Total liabilities $ 22,521 $ 15,925 $ 38,446 (1) The restricted investments as of December 31, 2023 and 2022 secure the Company’s irrevocable standby letters of credit obtained in connection with certain commercial agreements.
Schedule of Liabilities Measured at Fair Value Using Level 3 Inputs	Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following tables represent a roll-forward of contingent consideration. Contingent consideration as of December 31, 2022 $ 15,925 Milestone payments to Ares Trading S.A. (Merck Serono) (16,255) Realized foreign exchange gain on settlement of contingent consideration 330 Contingent consideration as of December 31, 2023 $ —

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)	12 Months Ended
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Aggregate Notional Amounts Outstanding	The following table summarizes the aggregate notional amounts for the Company’s derivatives outstanding as of the periods presented. Forward Contracts December 31, 2023 December 31, 2022 Derivatives designated as hedging instruments: Sell $ 1,249,662 $ 808,635 Purchase $ 198,408 $ 177,393 Derivatives not designated as hedging instruments: Sell $ 350,269 $ 218,903 Purchase $ 90,102 $ 6,785
Schedule of Fair Value Carrying Amount of Derivative Instruments	The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows: Balance Sheet Location December 31, 2023 December 31, 2022 Derivatives designated as hedging instruments: Asset Derivatives - Level 2 (1) Other current assets $ 6,663 $ 19,464 Other assets 1,855 2,059 Subtotal $ 8,518 $ 21,523 Liability Derivatives - Level 2 (1) Accounts payable and accrued liabilities $ 30,005 $ 12,130 Other long-term liabilities 8,171 1,074 Subtotal $ 38,176 $ 13,204 Derivatives not designated as hedging instruments: Asset Derivatives - Level 2 (1) Other current assets $ 547 $ 1,472 Liability Derivatives - Level 2 (1) Accounts payable and accrued liabilities $ 3,848 $ 471 Total Derivatives Assets $ 9,065 $ 22,995 Total Derivatives Liabilities $ 42,024 $ 13,675 (1) Refer to Note 1 to these Consolidated Financial Statements for additional information related to the Company’s fair value measurements.
Schedule of Impact of Gains and Losses from Consolidated Statements of Operations	The following tables summarize the impact of gains and losses from the Company's derivatives on its Consolidated Statements of Operations for the periods presented. Years Ended December 31, 2023 2022 Derivatives Designated as Cash Flow Hedging Instruments Cash Flow Hedging Gains (Losses) Cash Flow Hedging Gains (Losses) Net product revenues $ (186) $ 48,541 Operating expenses $ 350 $ (11,917) Derivatives Not Designated as Hedging Instruments Gains (Losses) Recognized in Earnings Gains (Losses) Recognized in Earnings Operating expenses $ (8,808) $ 872

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2023
Leases [Abstract]
Schedule of ROU Assets and Lease Liabilities	The following table presents the Company’s ROU assets and lease liabilities for the periods presented. December 31, Lease Classification Classification 2023 2022 Assets: Operating Other assets $ 42,731 $ 34,935 Financing Other assets 3,343 6,021 Total ROU assets $ 46,074 $ 40,956 Liabilities: Current: Operating Accounts payable and accrued liabilities $ 8,640 $ 8,088 Financing Accounts payable and accrued liabilities 139 2,287 Noncurrent: Operating Other long-term liabilities 38,047 26,329 Financing Other long-term liabilities 77 184 Total lease liabilities $ 46,903 $ 36,888
Schedule of Maturities of Finance Lease Liabilities	Maturities of lease liabilities as of December 31, 2023 by fiscal year were as follows: Maturity of Lease Liabilities Operating Financing Total 2024 $ 11,217 $ 142 $ 11,359 2025 9,861 75 9,936 2026 7,966 6 7,972 2027 7,064 — 7,064 2028 6,508 — 6,508 Thereafter 15,811 — 15,811 Total lease payments 58,427 223 58,650 Less: Interest (11,740) (7) (11,747) Present value of lease liabilities $ 46,687 $ 216 $ 46,903
Schedule of Maturities of Operating Lease Liabilities	Maturities of lease liabilities as of December 31, 2023 by fiscal year were as follows: Maturity of Lease Liabilities Operating Financing Total 2024 $ 11,217 $ 142 $ 11,359 2025 9,861 75 9,936 2026 7,966 6 7,972 2027 7,064 — 7,064 2028 6,508 — 6,508 Thereafter 15,811 — 15,811 Total lease payments 58,427 223 58,650 Less: Interest (11,740) (7) (11,747) Present value of lease liabilities $ 46,687 $ 216 $ 46,903
Schedule of Lease Cost	Lease costs associated with payments under the Company’s leases for the periods presented were as follows: Years Ended December 31, Lease Cost Classification 2023 2022 Operating (1) Operating expenses $ 14,197 $ 13,669 Financing: Amortization Operating expenses 3,360 2,858 Interest expense Interest expense 2,648 163 Total lease costs $ 20,205 $ 16,690 (1) Includes short-term leases and variable lease costs, both of which were not material in the periods presented. Years Ended December 31, Supplemental Cash Flow Information 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Cash used in operating activities: Operating leases $ 9,980 $ 10,760 Financing leases $ 51 $ 165 Cash used in financing activities: Financing leases $ 2,286 $ 2,605 ROU assets obtained in exchange for lease obligations: Operating leases $ 16,321 $ 5,252 Financing leases $ 68 $ 878
Schedule of Other Information	The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities: Years Ended December 31, Other Information 2023 2022 Weighted average remaining lease term (in years): Operating leases 6.8 5.2 Financing leases 1.6 1.7 Weighted average discount rate: Operating leases 5.9 % 5.1 % Financing leases 3.1 % 5.4 %

DEBT (Tables)

DEBT (Tables)	12 Months Ended
DEBT (Tables)	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Senior Subordinated Convertible Obligations	The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt: December 31, 2023 2022 0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes) $ 495,000 $ 495,000 Unamortized discount net of deferred offering costs (1,123) (3,040) 2024 Notes, net (1) 493,877 491,960 1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes) 600,000 600,000 Unamortized discount net of deferred offering costs (6,905) (8,941) 2027 Notes, net 593,095 591,059 Total convertible debt, net $ 1,086,972 $ 1,083,019 Fair value of fixed-rate convertible debt (2) : 2024 Notes $ 488,288 $ 526,230 2027 Notes 619,260 647,370 Total fair value of fixed-rate convertible debt $ 1,107,548 $ 1,173,600 (1) As the 2024 Notes mature in August 2024, the outstanding principal of the 2024 Notes is classified as a current liability as of December 31, 2023. (2) The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. See Note 1 to these Consolidated Financial Statements for additional discussion of fair value measurements.
Schedule of Interest Expense on Fixed-Rate Convertible Debt	Interest expense on the Company’s fixed-rate convertible debt consisted of the following: Years Ended December 31, 2023 2022 2021 Coupon interest expense $ 10,465 $ 10,465 $ 10,465 Accretion of discount on convertible notes 3,359 3,349 3,339 Amortization of debt issuance costs 594 593 593 Total interest expense on convertible debt $ 14,418 $ 14,407 $ 14,397

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)	12 Months Ended
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)	Dec. 31, 2023
Equity [Abstract]
Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI	The following table summarizes changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI, for the periods presented. Unrealized Gains (Losses) on Cash Flow Hedges Unrealized Gains (Losses) on Available-for-Sale Debt Securities Total AOCI balance at December 31, 2020 $ (20,028) $ 3,889 $ (16,139) Other comprehensive income (loss) before 34,379 (6,858) 27,521 Less: gain (loss) reclassified from AOCI (1,454) — (1,454) Tax effect — 1,596 1,596 Net current period other comprehensive income (loss) 35,833 (5,262) 30,571 AOCI balance at December 31, 2021 $ 15,805 $ (1,373) $ 14,432 Other comprehensive income (loss) before 29,045 (13,967) 15,078 Less: gain (loss) reclassified from AOCI 36,624 — 36,624 Tax effect — 3,247 3,247 Net current period other comprehensive income (loss) (7,579) (10,720) (18,299) AOCI balance at December 31, 2022 $ 8,226 $ (12,093) $ (3,867) Other comprehensive income (loss) before (37,720) 16,885 (20,835) Less: gain (loss) reclassified from AOCI 164 — 164 Tax effect — (3,922) (3,922) Net current period other comprehensive income (loss) (37,884) 12,963 (24,921) AOCI balance at December 31, 2023 $ (29,658) $ 870 $ (28,788)

REVENUE, CREDIT CONCENTRATION_2

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2023
Risks and Uncertainties [Abstract]
Schedule of Total Revenues and Disaggregates Net Product Revenues by Product	The following table presents Total Revenues and disaggregates Net Product Revenues by product. Years Ended December 31, 2023 2022 2021 Enzyme product revenues: VIMIZIM $ 701,053 $ 663,739 $ 623,145 NAGLAZYME 420,292 443,794 380,449 PALYNZIQ 303,919 255,032 237,474 BRINEURA 161,889 154,333 128,034 ALDURAZYME 131,248 128,422 122,765 Total enzyme product revenues 1,718,401 1,645,320 1,491,867 VOXZOGO 469,881 169,128 5,855 KUVAN 180,767 227,577 285,776 ROCTAVIAN 3,489 — — Total net product revenues 2,372,538 2,042,025 1,783,498 Royalty and other revenues 46,688 54,014 62,777 Total revenues $ 2,419,226 $ 2,096,039 $ 1,846,275
Schedule of Disaggregation of Total Net Product Revenues by Geographic Region	The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is distributed, marketed and sold exclusively by Sanofi worldwide. Years Ended December 31, 2023 2022 2021 United States $ 771,314 $ 684,284 $ 657,700 Europe 669,331 650,952 558,952 Latin America 332,437 266,801 191,151 Rest of world 468,208 311,566 252,930 Total net product revenues marketed by the Company 2,241,290 1,913,603 1,660,733 ALDURAZYME net product revenues marketed by Sanofi 131,248 128,422 122,765 Total net product revenues $ 2,372,538 $ 2,042,025 $ 1,783,498
Schedule of Total Net Product Revenues Attributed to Largest Customers	The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. Years Ended December 31, 2023 2022 2021 Customer A 14 % 16 % 18 % Customer B 12 % 12 % 14 % Customer C 10 % 9 % 10 % Total 36 % 37 % 42 %
Schedule of Long-Lived Assets by Geographic Region	Long-lived assets, which consist of net property, plant and equipment and ROU assets are summarized by geographic region in the following table. December 31, 2023 2022 Long-lived assets by geography: United States $ 788,590 $ 786,509 Ireland 306,542 309,180 Rest of world 17,075 18,633 Total long-lived assets $ 1,112,207 $ 1,114,322

EQUITY COMPENSATION PLANS AND_2

EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense included on the Company’s Consolidated Statements of Operations for all stock-based compensation arrangements was as follows: Years Ended December 31, 2023 2022 2021 Cost of sales $ 17,604 $ 17,709 $ 22,357 Research and development 65,714 61,702 67,196 Selling, general and administrative 123,781 116,897 107,710 Total stock-based compensation expense $ 207,099 $ 196,308 $ 197,263
Schedule of Restricted Stock Unit Activity	Below is a summary of activity related to RSUs with service-based vesting conditions for the year ended December 31, 2023: Shares Weighted Non-vested units as of December 31, 2022 4,519,746 $ 79.55 Granted 2,150,561 $ 88.96 Vested (1,666,477) $ 80.68 Forfeited (300,005) $ 81.35 Non-vested units as of December 31, 2023 4,703,825 $ 83.39 Below is a summary of activity related to RSUs with vesting conditions based on performance targets for the year ended December 31, 2023: Shares Weighted Average Grant Date Fair Value Non-vested units as of December 31, 2022 447,662 $ 78.78 Granted 230,019 $ 89.22 Vested (231,346) $ 78.30 Forfeited (10,235) $ 78.36 Non-vested units as of December 31, 2023 436,100 $ 83.33 Below is a summary of activity related to RSUs with market-based vesting conditions for the year ended December 31, 2023: Shares Weighted Average Grant Date Fair Value Non-vested units as of December 31, 2022 396,120 $ 119.61 Granted 261,570 $ 132.56 Vested (248,940) $ 116.05 Forfeited (4,850) $ 121.04 Non-vested units as of December 31, 2023 403,900 $ 128.95
Schedule of Fair Value of TSR-RSUs Granted Assumptions	The grant date fair values and assumptions used to determine the fair value of TSR-RSUs on grant date during the periods presented were as follows: Years Ended December 31, 2023 2022 2021 Grant date fair value $132.56 124.67 $117.52 Expected volatility 22.4 – 152.1% 24.5 – 157.6% 24.7 – 161.7% Dividend yield 0.0% 0.0% 0.0% Expected term 2.8 years 2.8 years 2.8 years Risk-free interest rate 3.8% 2.0% 0.3%
Schedule of Stock Option Activity	The following table summarizes activity under the Company’s stock option plans for the year ended December 31, 2023. All stock option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: Shares Weighted Average Exercise Price Weighted Average Remaining Years Aggregate Intrinsic Value (1) Options outstanding as of December 31, 2022 5,943,535 $ 82.41 $ 132,395 Granted 704,589 $ 89.47 Exercised (837,623) $ 68.82 Expired and forfeited (90,370) $ 82.69 Options outstanding as of December 31, 2023 5,720,131 $ 85.26 5.0 $ 74,704 Options unvested as of December 31, 2023 1,260,219 $ 84.63 8.7 $ 15,139 Exercisable at December 31, 2023 4,459,912 $ 85.44 4.0 $ 59,566 (1) The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock on the Nasdaq Global Select Market as of the last trading day for the respective year. The aggregate intrinsic value of options outstanding and exercisable includes options with an exercise price below $96.42, the closing price of the Company’s common stock on the Nasdaq Global Select Market on December 29, 2023.
Schedule of Fair Value of Stock Options Granted Assumptions	The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows: Years Ended December 31, 2023 2022 2021 Expected volatility 37.8 – 40.3% 38.1 – 40.5% 39.4 – 41.6% Dividend yield 0.0% 0.0% 0.0% Expected term 4.7 – 6.2 years 4.7 – 6.1 years 4.7 – 6.0 years Risk-free interest rate 3.5 – 4.6% 2.1 – 4.2% 0.7 – 1.3%
Schedule of Fair Value of Stock Purchase Rights Granted Under the ESPP	The assumptions used to estimate the per share fair value of stock purchase rights granted under the ESPP were as follows: Years Ended December 31, 2023 2022 2021 Expected volatility 24.0 – 48.0% 28.6 – 69.2% 23.7 – 69.2% Dividend yield 0.0% 0.0% 0.0% Expected term 0.5 – 2.0 years 0.5 – 2.0 years 0.5 – 2.0 years Risk-free interest rate 0.06 – 5.5% 0.04 – 4.8% 0.04 – 2.4%

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
INCOME TAXES (Tables)	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Provision for (Benefit from) Income Taxes Based on Income (Loss) Before Income Taxes	The Provision for (Benefit from) Income Taxes was based on Income (Loss) before Income Taxes as follows: Years Ended December 31, 2023 2022 2021 U.S. Source $ (453,840) $ (299,403) $ (259,258) Non-U.S. Source 642,403 448,979 183,908 Income (loss) before income taxes $ 188,563 $ 149,576 $ (75,350)
Schedule of Components of Provision for (Benefit from) Income Taxes	The U.S. and foreign components of the Provision for (Benefit from) Income Taxes were as follows: Years Ended December 31, 2023 2022 2021 Provision for (benefit from) income taxes Federal $ 25,120 $ 12,798 $ (2,038) State and local 5,098 5,058 1,339 Foreign 35,681 42,246 5,037 65,899 60,102 4,338 Provision for (benefit from) deferred income taxes: Federal (70,754) (79,270) (29,895) State and local (8,030) (5,143) (1,230) Foreign 33,803 32,326 15,517 (44,981) (52,087) (15,608) Provision for (benefit from) income taxes $ 20,918 $ 8,015 $ (11,270)
Schedule of Reconciliation of Statutory Federal Income Tax Benefit to Effective Tax Rate	The following is a reconciliation of the statutory federal income tax benefit to the Company’s effective tax rate: December 31, 2023 2022 2021 Federal statutory income tax rate $ 39,598 $ 31,412 $ (15,824) State and local taxes (3,614) (1,017) 509 Orphan Drug & General Business Credit (39,535) (35,674) (29,363) Stock compensation expense 2,209 6,433 7,859 Foreign Source Income Subject to US Tax 47,721 (5,644) 16,878 Foreign tax rate differential (1) (69,987) (4,051) (16,971) Section 162(m) limitation 9,699 6,577 6,304 Tax Reserves 27,296 18,043 15,530 Intra-entity transfer of assets 5,019 (18,752) (3,920) Valuation allowance/deferred benefit 3,723 7,851 6,821 Other (1,211) 2,837 907 Effective income tax rate $ 20,918 $ 8,015 $ (11,270) (1) For the year ended December 31, 2023, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate. For the year ended December 31, 2022, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and was offset by the income from the sale of a priority review voucher that was taxed at a higher tax rate. For the year ended December 31, 2021, the foreign rate differential included foreign local tax expense which was at an effective rate lower than the U.S. statutory rate and includes the recognition of the valuation allowance against a portion of the deferred tax assets of the Company’s Dutch subsidiary of $9.3 million.
Schedule of Components of Net Deferred Tax Assets	The significant components of the Company’s net deferred tax assets were as follows: December 31, 2023 2022 Net deferred tax assets: Net operating loss carryforwards $ 19,025 $ 20,657 Tax credit carryforwards 524,652 555,319 Accrued expenses, reserves, and prepaids 107,485 88,697 Intangible assets 789,479 836,402 Capitalized research and development expenses 216,975 103,212 Stock-based compensation 48,744 49,472 Lease liabilities 7,857 5,757 Inventory 18,914 22,726 Other 1,113 5,596 Valuation allowance (119,230) (116,299) Total deferred tax assets 1,615,014 1,571,539 Joint venture basis difference (1,111) (745) Acquired intangibles (1,026) (1,138) ROU Assets (6,917) (5,347) Property, plant and equipment (60,151) (58,897) Total deferred tax liabilities (69,205) (66,127) Net deferred tax assets $ 1,545,809 $ 1,505,412
Schedule of Net Operating Loss and Tax Credit Carryforwards	As of December 31, 2023, the Company had the following net operating loss and tax credit carryforwards, which if not utilized, will expire as follows: Type Amount Year Federal net operating loss carryforwards $ 3,296 2030-2033 Federal R&D and orphan drug credit carryforwards $ 555,074 2024-2043 State net operating loss carryforwards $ 208,592 2024-2043 Dutch net operating loss carryforwards $ 31,361 Indefinite
Schedule of Reconciliation of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December 31, 2023 and 2022, is as follows: December 31, 2023 2022 Balance at beginning of period $ 232,856 $ 205,095 Additions based on tax positions related to the current year 41,473 26,762 Additions for tax positions of prior years 3,127 1,017 Lapse of statute of limitations — (18) Balance at end of period $ 277,456 $ 232,856

EARNINGS (LOSS) PER COMMON SH_2

EARNINGS (LOSS) PER COMMON SHARE (Tables)	12 Months Ended
EARNINGS (LOSS) PER COMMON SHARE (Tables)	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Earnings (Loss) Per Common Share	The following table sets forth the computation of basic and diluted earnings (loss) per common share (common shares in thousands): Twelve Months Ended 2023 2022 2021 Numerator: Net income (loss) $ 167,645 $ 141,561 $ (64,080) Denominator: Weighted-average common shares outstanding, basic 187,834 185,266 182,852 Effect of dilutive securities: Common stock issuable under the Company's equity incentive plans 3,761 3,697 — Weighted-average common shares outstanding, diluted 191,595 188,963 182,852 Earnings (loss) per common share, basic $ 0.89 $ 0.76 $ (0.35) Earnings (loss) per common share, diluted $ 0.87 $ 0.75 $ (0.35)
Schedule of Anti-Dilutive Common Stock Excluded from Computation of Basic and Diluted Earnings (Loss) Per Share	In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings (loss) per common share as they were anti-dilutive (in thousands): Twelve Months Ended 2023 2022 2021 Common stock issuable under the Company's equity incentive plans 8,072 8,148 12,450 Common stock issuable under the Company’s convertible debt (1) 8,335 8,335 8,335 Total number of potentially issuable shares 16,407 16,483 20,785 (1) If converted, the Company would issue 4.0 million shares under the 2024 Notes and 4.4 million shares under the 2027 Notes. For additional discussion of our convertible debt, see Note 10

BUSINESS OVERVIEW AND SIGNIFI_4

BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($) segment tranche	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Significant Accounting Policies [Line Items]
Capitalized cost	$ 30.6
Payment term after customer control	1 year
Period between customer control and payment	1 year
Advertising expenses	$ 27.8	$ 25.2	$ 30.2
Number of tranches in offering period \| tranche	4
Span of offering period	24 months
Foreign currency transaction losses	$ 27.7	$ 11.4	$ 11.7
Number of reportable segment \| segment	1
Number of operating segments \| segment	1
Minimum \| ALDURAZYME
Significant Accounting Policies [Line Items]
Payment received as percentage of net product sales	39.50%
Maximum \| ALDURAZYME
Significant Accounting Policies [Line Items]
Payment received as percentage of net product sales	50%

BUSINESS OVERVIEW AND SIGNIFI_5

BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property, Plant and Equipment Estimated Useful Lives (Details)	Dec. 31, 2023
Building and improvements \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life, (in years)	20 years
Building and improvements \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life, (in years)	50 years
Manufacturing and laboratory equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life, (in years)	5 years
Manufacturing and laboratory equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life, (in years)	15 years
Computer hardware and software \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life, (in years)	3 years
Computer hardware and software \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life, (in years)	7 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life, (in years)	5 years
Land improvements \| Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life, (in years)	10 years
Land improvements \| Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life, (in years)	20 years

FINANCIAL INSTRUMENTS - Schedul

FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 1,683,827	$ 1,641,139
Gross Unrealized Gains	4,388	159
Gross Unrealized Losses	(3,270)	(15,926)
Aggregate Fair Value	1,684,945	1,625,372
Cash and Cash Equivalents	755,127	724,531
Short-term Marketable Securities	318,683	567,006
Long-term Marketable Securities	611,135	333,835
Level 1
Schedule of Available-for-sale Securities [Line Items]
Cash, amortized cost	229,676	463,248
Cash, aggregate fair value	229,676	463,248
Level 2
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,454,151	1,177,891
Gross Unrealized Gains	4,388	159
Gross Unrealized Losses	(3,270)	(15,926)
Aggregate Fair Value	1,455,269	1,162,124
Cash and Cash Equivalents	525,451	261,283
Short-term Marketable Securities	318,683	567,006
Long-term Marketable Securities	611,135	333,835
Level 2 \| Money market instruments
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	499,483	248,933
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	499,483	248,933
Cash and Cash Equivalents	499,483	248,933
Short-term Marketable Securities	0	0
Long-term Marketable Securities	0	0
Level 2 \| Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	587,896	504,984
Gross Unrealized Gains	3,476	34
Gross Unrealized Losses	(1,996)	(11,541)
Aggregate Fair Value	589,376	493,477
Cash and Cash Equivalents	0	1,881
Short-term Marketable Securities	193,251	299,153
Long-term Marketable Securities	396,125	192,443
Level 2 \| U.S. government agency securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	251,952	48,103
Gross Unrealized Gains	556	11
Gross Unrealized Losses	(1,140)	(22)
Aggregate Fair Value	251,368	48,092
Cash and Cash Equivalents	19,976	10,469
Short-term Marketable Securities	111,343	37,623
Long-term Marketable Securities	120,049	0
Level 2 \| Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	20,076	312,720
Gross Unrealized Gains	5	45
Gross Unrealized Losses	0	(3,771)
Aggregate Fair Value	20,081	308,994
Cash and Cash Equivalents	5,992	0
Short-term Marketable Securities	14,089	229,846
Long-term Marketable Securities	0	79,148
Level 2 \| Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	94,744	63,151
Gross Unrealized Gains	351	69
Gross Unrealized Losses	(134)	(592)
Aggregate Fair Value	94,961	62,628
Cash and Cash Equivalents	0	0
Short-term Marketable Securities	0	384
Long-term Marketable Securities	$ 94,961	$ 62,244
Maximum
Schedule of Available-for-sale Securities [Line Items]
Short-term marketable securities maturity period	1 year	1 year
Long-term marketable securities maturity period	5 years	5 years
Minimum
Schedule of Available-for-sale Securities [Line Items]
Long-term marketable securities maturity period	1 year	1 year

FINANCIAL INSTRUMENTS - Narrati

FINANCIAL INSTRUMENTS - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Available-for-sale Securities [Line Items]
Impairment of assets	$ 12.6
Fair Value, Measurements, Recurring \| Strategic Investment
Schedule of Available-for-sale Securities [Line Items]
Strategic investments fair value	$ 11.3	$ 23.9

INTANGIBLE ASSETS - Schedule of

INTANGIBLE ASSETS - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-lived intangible assets	$ 710,011	$ 690,871
Accumulated amortization	(415,310)	(352,302)
Net carrying value	$ 294,701	$ 338,569

INTANGIBLE ASSETS - Schedule _2

INTANGIBLE ASSETS - Schedule of Carrying Value and Estimated Remaining Life of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Net Balance	$ 294,701	$ 338,569
Acquired intellectual property
Finite-Lived Intangible Assets [Line Items]
Net Balance	$ 185,344
Average Remaining Life	4 years 4 months 24 days
Technology transfer
Finite-Lived Intangible Assets [Line Items]
Net Balance	$ 89,221
Average Remaining Life	4 years 4 months 24 days
License payments
Finite-Lived Intangible Assets [Line Items]
Net Balance	$ 20,136
Average Remaining Life	9 years 9 months 18 days

INTANGIBLE ASSETS - Schedule _3

INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 58,200
2025	38,924
2026	38,924
2027	38,924
2028	23,174
Thereafter	7,293
Finite-lived intangible asset future amortization	$ 205,439

PROPERTY, PLANT AND EQUIPMENT -

PROPERTY, PLANT AND EQUIPMENT - Schedule of Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,933,222	$ 1,933,222	$ 1,875,511
Accumulated depreciation	(867,089)	(867,089)	(802,145)
Total property, plant and equipment, net	1,066,133	1,066,133	1,073,366
Impairment of assets		38,608	0	$ 0
Building and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	860,807	860,807	819,100
Manufacturing and laboratory equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	538,677	538,677	475,663
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	211,482	211,482	214,829
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	90,781	90,781	90,786
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	58,230	58,230	59,532
Furniture and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	46,453	46,453	45,762
Land improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	26,779	26,779	26,455
Construction-in-progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	100,013	$ 100,013	$ 143,384
Impairment of assets	$ 14,000

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 40.3	$ 38.6	$ 46.1

INVENTORY (Details)

INVENTORY (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 155,704	$ 131,071
Work-in-process	571,107	410,656
Finished goods	380,372	352,356
Total inventory	$ 1,107,183	$ 894,083

SUPPLEMENTAL FINANCIAL STATEM_3

SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts payable and accrued operating expenses	$ 315,509	$ 231,238
Accrued compensation expense	201,067	207,573
Accrued rebates payable	96,179	72,654
Foreign currency exchange forward contracts	33,853	12,601
Accrued royalties payable	14,299	13,306
Lease liability	8,779	10,375
Accrued income taxes	2,651	16,213
Deferred revenue	4,620	711
Other	6,190	8,288
Total accounts payable and accrued liabilities	$ 683,147	$ 572,959

SUPPLEMENTAL FINANCIAL STATEM_4

SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION - Narrative (Details) - 2022 Restructuring Plan $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Supplemental Balance Sheet Information [Line Items]
Restructuring charges	$ 23
Accounts payable and accrued liabilities
Supplemental Balance Sheet Information [Line Items]
Restructuring reserve	$ 11.1

SUPPLEMENTAL FINANCIAL STATEM_5

SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION - Schedule of Estimated Accrued Rebates and Reserve for Cash Discounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accrued rebates
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 72,654	$ 47,987	$ 65,526
Provision for Current Period Sales	196,864	140,260	116,691
Payments	(173,339)	(115,593)	(134,230)
Balance at End of Period	96,179	72,654	47,987
Reserve for cash discounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	3,639	2,013	1,716
Provision for Current Period Sales	21,081	20,351	16,003
Payments	(19,330)	(18,725)	(15,706)
Balance at End of Period	$ 5,390	$ 3,639	$ 2,013

FAIR VALUE MEASUREMENTS - Sched

FAIR VALUE MEASUREMENTS - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Quoted Price in Active Markets For Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets remeasured	$ 0	$ 0
Financial liabilities remeasured	0	0
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other assets	30,512,000	22,296,000
Fair value of financial assets, Total	32,538,000	24,950,000
Fair value of current liabilities		18,579,000
Fair value of other long-term liabilities		19,867,000
Fair value of financial liabilities, Total	30,145,000	38,446,000
Fair Value, Measurements, Recurring \| NQDC Plan liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of current liabilities	2,026,000	2,654,000
Fair value of other long-term liabilities	28,119,000	19,867,000
Fair Value, Measurements, Recurring \| Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of current liabilities		15,925,000
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other assets	30,512,000	22,296,000
Fair value of financial assets, Total	32,538,000	24,950,000
Fair value of current liabilities		2,654,000
Fair value of other long-term liabilities		19,867,000
Fair value of financial liabilities, Total	30,145,000	22,521,000
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2) \| NQDC Plan liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of current liabilities	2,026,000	2,654,000
Fair value of other long-term liabilities	28,119,000	19,867,000
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2) \| Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of current liabilities		0
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other assets	0	0
Fair value of financial assets, Total	0	0
Fair value of current liabilities		15,925,000
Fair value of other long-term liabilities		0
Fair value of financial liabilities, Total	0	15,925,000
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3) \| NQDC Plan liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of current liabilities	0	0
Fair value of other long-term liabilities	0	0
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3) \| Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of current liabilities		15,925,000
Fair Value, Measurements, Recurring \| NQDC Plan assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current assets	2,026,000	2,654,000
Fair value of other assets	28,119,000	19,867,000
Fair Value, Measurements, Recurring \| NQDC Plan assets \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current assets	2,026,000	2,654,000
Fair value of other assets	28,119,000	19,867,000
Fair Value, Measurements, Recurring \| NQDC Plan assets \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current assets	0	0
Fair value of other assets	0	0
Fair Value, Measurements, Recurring \| Restricted investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other assets	2,393,000	2,429,000
Fair Value, Measurements, Recurring \| Restricted investments \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other assets	2,393,000	2,429,000
Fair Value, Measurements, Recurring \| Restricted investments \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other assets	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Sch_2

FAIR VALUE MEASUREMENTS - Schedule of Liabilities Measured at Fair Value Using Level 3 Inputs (Details) - Contingent Payment $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration, beginning balance	$ 15,925
Milestone payments to Ares Trading S.A. (Merck Serono)	(16,255)
Realized foreign exchange gain on settlement of contingent consideration	330
Contingent consideration, ending balance	$ 0

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Derivative [Line Items]
Unrealized losses reclassified from AOCI to earnings	$ 23.3
Derivatives designated as hedging instruments:
Derivative [Line Items]
Maturity of derivatives	2 years
Derivatives not designated as hedging instruments:
Derivative [Line Items]
Maturity of derivatives	3 months

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Aggregate Notional Amounts Outstanding (Details) - Foreign Exchange Contracts - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Derivatives designated as hedging instruments: \| Sell
Derivative [Line Items]
Notional amount	$ 1,249,662	$ 808,635
Derivatives designated as hedging instruments: \| Purchase
Derivative [Line Items]
Notional amount	198,408	177,393
Derivatives not designated as hedging instruments: \| Sell
Derivative [Line Items]
Notional amount	350,269	218,903
Derivatives not designated as hedging instruments: \| Purchase
Derivative [Line Items]
Notional amount	$ 90,102	$ 6,785

DERIVATIVE INSTRUMENTS AND HE_5

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Fair Value Carrying Amount of Derivative Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Derivative asset, fair value	$ 9,065	$ 22,995
Derivative liability, fair value	42,024	13,675
Derivatives designated as hedging instruments: \| Level 2
Derivative [Line Items]
Derivative asset, fair value	8,518	21,523
Derivative liability, fair value	38,176	13,204
Derivatives designated as hedging instruments: \| Level 2 \| Other current assets
Derivative [Line Items]
Derivative asset, fair value	6,663	19,464
Derivatives designated as hedging instruments: \| Level 2 \| Other assets
Derivative [Line Items]
Derivative asset, fair value	1,855	2,059
Derivatives designated as hedging instruments: \| Level 2 \| Accounts payable and accrued liabilities
Derivative [Line Items]
Derivative liability, fair value	30,005	12,130
Derivatives designated as hedging instruments: \| Level 2 \| Other long-term liabilities
Derivative [Line Items]
Derivative liability, fair value	8,171	1,074
Derivatives not designated as hedging instruments: \| Level 2 \| Other current assets
Derivative [Line Items]
Derivative asset, fair value	547	1,472
Derivatives not designated as hedging instruments: \| Level 2 \| Accounts payable and accrued liabilities
Derivative [Line Items]
Derivative liability, fair value	$ 3,848	$ 471

DERIVATIVE INSTRUMENTS AND HE_6

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Impact of Gains and Losses from Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Derivatives designated as hedging instruments: \| Operating expenses \| Unrealized Gains (Losses) on Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Cash Flow Hedging Gains (Losses) Reclassified into Earnings	$ 350	$ (11,917)
Derivatives designated as hedging instruments: \| Net product revenues \| Unrealized Gains (Losses) on Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Cash Flow Hedging Gains (Losses) Reclassified into Earnings	(186)	48,541
Derivatives not designated as hedging instruments:
Derivative Instruments, Gain (Loss) [Line Items]
Gains (Losses) Recognized in Earnings	$ (8,808)	$ 872

LEASES - Schedule of ROU Assets

LEASES - Schedule of ROU Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets:
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Operating	$ 42,731	$ 34,935
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Financing	$ 3,343	$ 6,021
Total ROU assets	$ 46,074	$ 40,956
Liabilities:
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accounts payable and accrued liabilities	Accounts payable and accrued liabilities
Operating, current	$ 8,640	$ 8,088
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accounts payable and accrued liabilities	Accounts payable and accrued liabilities
Finance, current	$ 139	$ 2,287
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long-term liabilities	Other long-term liabilities
Operating, noncurrent	$ 38,047	$ 26,329
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long-term liabilities	Other long-term liabilities
Finance, noncurrent	$ 77	$ 184
Total lease liabilities	$ 46,903	$ 36,888

LEASES - Schedule of Maturities

LEASES - Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Operating
2024	$ 11,217
2025	9,861
2026	7,966
2027	7,064
2028	6,508
Thereafter	15,811
Total lease payments	58,427
Less: Interest	(11,740)
Present value of lease liabilities	46,687
Financing
2024	142
2025	75
2026	6
2027	0
2028	0
Thereafter	0
Total lease payments	223
Less: Interest	(7)
Present value of lease liabilities	216
Total
2024	11,359
2025	9,936
2026	7,972
2027	7,064
2028	6,508
Thereafter	15,811
Total lease payments	58,650
Less: Interest	(11,747)
Total lease liabilities	$ 46,903	$ 36,888

LEASES - Schedule of Lease Cost

LEASES - Schedule of Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Lease Cost
Total lease costs	$ 20,205	$ 16,690
Operating expenses
Lease Cost
Operating	14,197	13,669
Amortization	3,360	2,858
Interest expense
Lease Cost
Interest expense	$ 2,648	$ 163

LEASES - Schedule of Other Info

LEASES - Schedule of Other Information (Details)	Dec. 31, 2023	Dec. 31, 2022
Weighted average remaining lease term (in years):
Operating leases	6 years 9 months 18 days	5 years 2 months 12 days
Financing leases	1 year 7 months 6 days	1 year 8 months 12 days
Weighted average discount rate:
Operating leases	5.90%	5.10%
Financing leases	3.10%	5.40%

LEASES - Schedule of Supplement

LEASES - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash used in operating activities:
Operating leases	$ 9,980	$ 10,760
Financing leases	51	165
Cash used in financing activities:
Financing leases	2,286	2,605	$ 3,039
ROU assets obtained in exchange for lease obligations:
Operating leases	16,321	5,252
Financing leases	$ 68	$ 878

DEBT - Narrative (Details)

DEBT - Narrative (Details)	1 Months Ended		12 Months Ended
DEBT - Narrative (Details)	May 31, 2020 USD ($) $ / shares	Aug. 31, 2017 USD ($) $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Oct. 31, 2018 USD ($)
Debt Instrument [Line Items]
Carrying value of equity component			$ 1,100,000,000
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)
Debt Instrument [Line Items]
Carrying value of equity component			$ 495,000,000	$ 495,000,000
Debt instrument, interest rate, stated percentage, per annum			0.599%	0.599%
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes) \| Senior Subordinated Notes
Debt Instrument [Line Items]
Debt instrument, aggregate principal amount		$ 495,000,000
Debt instrument percentage of face value		98%
Debt instrument, interest rate, stated percentage, per annum		0.599%
Conversion rate of shares		0.0080212
Debt instrument, convertible, conversion price, per share (in dollars per share) \| $ / shares		$ 124.67
Net proceeds from offering debt		$ 481,700,000
Debt Instrument, unamortized discount		$ 9,900,000
Repurchase of note principal amount (as a percent)			100%
1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes)
Debt Instrument [Line Items]
Carrying value of equity component			$ 600,000,000	$ 600,000,000
Debt instrument, interest rate, stated percentage, per annum			1.25%	1.25%
1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes) \| Senior Subordinated Notes
Debt Instrument [Line Items]
Debt instrument, aggregate principal amount	$ 600,000,000
Debt instrument, interest rate, stated percentage, per annum	1.25%
Conversion rate of shares	0.0072743
Debt instrument, convertible, conversion price, per share (in dollars per share) \| $ / shares	$ 137.47
Net proceeds from offering debt	$ 585,800,000
Debt Instrument, unamortized discount	$ 13,500,000
Repurchase of note principal amount (as a percent)			100%
The 2018 Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 200,000,000
Outstanding amount			$ 0

DEBT - Schedule of Senior Subor

DEBT - Schedule of Senior Subordinated Convertible Obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Convertible notes	$ 1,100,000
Convertible notes, current, net of unamortized discount and deferred offering costs	493,877	$ 0
Convertible notes, noncurrent, net of unamortized discount and deferred offering costs	593,095	1,083,019
Total convertible debt, net	1,086,972	1,083,019
Total fair value of fixed-rate convertible debt	$ 1,107,548	$ 1,173,600
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage, per annum	0.599%	0.599%
Convertible notes	$ 495,000	$ 495,000
Unamortized discount net of deferred offering costs	(1,123)	(3,040)
Convertible notes, current, net of unamortized discount and deferred offering costs	493,877
Convertible notes, noncurrent, net of unamortized discount and deferred offering costs		491,960
Total fair value of fixed-rate convertible debt	$ 488,288	$ 526,230
1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage, per annum	1.25%	1.25%
Convertible notes	$ 600,000	$ 600,000
Unamortized discount net of deferred offering costs	(6,905)	(8,941)
Convertible notes, noncurrent, net of unamortized discount and deferred offering costs	593,095	591,059
Total fair value of fixed-rate convertible debt	$ 619,260	$ 647,370

DEBT - Schedule of Interest Exp

DEBT - Schedule of Interest Expense on Fixed-Rate Convertible Debt (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Interest Expenses [Line Items]
Total interest expense on convertible debt	$ 17,335	$ 15,970	$ 15,337
Convertible Senior Notes
Schedule Of Interest Expenses [Line Items]
Coupon interest expense	10,465	10,465	10,465
Accretion of discount on convertible notes	3,359	3,349	3,339
Amortization of debt issuance costs	594	593	593
Total interest expense on convertible debt	$ 14,418	$ 14,407	$ 14,397

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Total stockholders' equity, beginning balances	$ 4,603,156	$ 4,265,669	$ 4,100,931
Other comprehensive income (loss) before reclassifications	(20,835)	15,078	27,521
Less: gain (loss) reclassified from AOCI	164	36,624	(1,454)
Tax effect	(3,922)	3,247	1,596
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX	(24,921)	(18,299)	30,571
Total stockholders' equity, ending balances	4,951,549	4,603,156	4,265,669
Accumulated other comprehensive income (loss):
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Total stockholders' equity, beginning balances	(3,867)	14,432	(16,139)
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX	(24,921)	(18,299)	30,571
Total stockholders' equity, ending balances	(28,788)	(3,867)	14,432
Unrealized Gains (Losses) on Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Total stockholders' equity, beginning balances	8,226	15,805	(20,028)
Other comprehensive income (loss) before reclassifications	(37,720)	29,045	34,379
Less: gain (loss) reclassified from AOCI	164	36,624	(1,454)
Tax effect	0	0	0
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX	(37,884)	(7,579)	35,833
Total stockholders' equity, ending balances	(29,658)	8,226	15,805
Unrealized Gains (Losses) on Available-for-Sale Debt Securities
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Total stockholders' equity, beginning balances	(12,093)	(1,373)	3,889
Other comprehensive income (loss) before reclassifications	16,885	(13,967)	(6,858)
Less: gain (loss) reclassified from AOCI	0	0	0
Tax effect	(3,922)	3,247	1,596
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX	12,963	(10,720)	(5,262)
Total stockholders' equity, ending balances	$ 870	$ (12,093)	$ (1,373)

REVENUE, CREDIT CONCENTRATION_3

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Revenues and Disaggregates Net Product Revenues by Product (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue from External Customer [Line Items]
Revenue	$ 2,419,226	$ 2,096,039	$ 1,846,275
Product
Revenue from External Customer [Line Items]
Revenue	2,372,538	2,042,025	1,783,498
Total enzyme product revenues
Revenue from External Customer [Line Items]
Revenue	1,718,401	1,645,320	1,491,867
VIMIZIM
Revenue from External Customer [Line Items]
Revenue	701,053	663,739	623,145
NAGLAZYME
Revenue from External Customer [Line Items]
Revenue	420,292	443,794	380,449
PALYNZIQ
Revenue from External Customer [Line Items]
Revenue	303,919	255,032	237,474
BRINEURA
Revenue from External Customer [Line Items]
Revenue	161,889	154,333	128,034
ALDURAZYME
Revenue from External Customer [Line Items]
Revenue	131,248	128,422	122,765
ALDURAZYME \| Marketed by Sanofi
Revenue from External Customer [Line Items]
Revenue	131,248	128,422	122,765
VOXZOGO
Revenue from External Customer [Line Items]
Revenue	469,881	169,128	5,855
KUVAN
Revenue from External Customer [Line Items]
Revenue	180,767	227,577	285,776
ROCTAVIAN
Revenue from External Customer [Line Items]
Revenue	3,489	0	0
Royalty and other revenues
Revenue from External Customer [Line Items]
Revenue	$ 46,688	$ 54,014	$ 62,777

REVENUE, CREDIT CONCENTRATION_4

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 2,419,226	$ 2,096,039	$ 1,846,275
ALDURAZYME
Disaggregation of Revenue [Line Items]
Revenue	131,248	128,422	122,765
Product
Disaggregation of Revenue [Line Items]
Revenue	2,372,538	2,042,025	1,783,498
Marketed by Company \| Products excluding ALDURAZYME
Disaggregation of Revenue [Line Items]
Revenue	2,241,290	1,913,603	1,660,733
Marketed by Company \| Products excluding ALDURAZYME \| United States
Disaggregation of Revenue [Line Items]
Revenue	771,314	684,284	657,700
Marketed by Company \| Products excluding ALDURAZYME \| Europe
Disaggregation of Revenue [Line Items]
Revenue	669,331	650,952	558,952
Marketed by Company \| Products excluding ALDURAZYME \| Latin America
Disaggregation of Revenue [Line Items]
Revenue	332,437	266,801	191,151
Marketed by Company \| Products excluding ALDURAZYME \| Rest of world
Disaggregation of Revenue [Line Items]
Revenue	468,208	311,566	252,930
Marketed by Sanofi \| ALDURAZYME
Disaggregation of Revenue [Line Items]
Revenue	$ 131,248	$ 128,422	$ 122,765

REVENUE, CREDIT CONCENTRATION_5

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenues Attributed to Largest Customers (Details) - Customer Concentration Risk - Net Product Revenue	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Customer A, B, & C
Concentration Risk [Line Items]
Concentration risk, percentage	36%	37%	42%
Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	14%	16%	18%
Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	12%	12%	14%
Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	10%	9%	10%

REVENUE, CREDIT CONCENTRATION_6

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Concentration Risk And Geographic Information [Line Items]
Accounts receivable, net	$ 633,704	$ 461,316
Customer
Concentration Risk And Geographic Information [Line Items]
Accounts receivable, net	$ 63,400	$ 68,800
Credit Concentration Risk \| Accounts Receivable Balance \| Customer One
Concentration Risk And Geographic Information [Line Items]
Concentration risk, percentage	15%	22%
Credit Concentration Risk \| Accounts Receivable Balance \| Customer Two
Concentration Risk And Geographic Information [Line Items]
Concentration risk, percentage	12%	15%

REVENUE, CREDIT CONCENTRATION_7

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Long-Lived Assets by Geographic Region (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	$ 1,112,207	$ 1,114,322
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	788,590	786,509
Ireland
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	306,542	309,180
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	$ 17,075	$ 18,633

EQUITY COMPENSATION PLANS AND_3

EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, shares in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, authorized (in shares)	52.3
Span of offering period, in years	24 months
Stock-based compensation expense capitalized to inventory	$ 21,700,000	$ 21,300,000	$ 20,000,000
Weighted-average fair value per option granted (in dollars per share)	$ 39.30	$ 32.45	$ 31.61
Total intrinsic value of options exercised	$ 25,900,000	$ 32,100,000	$ 40,700,000
Net tax benefit from stock options exercised	$ 2,300,000
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, authorized (in shares)	7
Shares reserved for future issuance (in shares)	2.5
Options to purchase shares of common stock, percentage	85%
Span of offering period, in years	2 years
Maximum percentage of qualified compensation to be used for purchase	10%
Maximum payroll deductions	$ 25,000
Shares issued under the employee stock purchase plan (in shares)	0.3
Unrecognized compensation cost related to unvested awards	$ 14,200,000
Unrecognized compensation cost expected to recognized over weighted average period, in years	1 year 4 months 24 days
Restricted Stock with Service Based Vesting Conditions
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value per RSU granted (in dollars per share)	$ 88.96	$ 79.43	$ 78.46
The total intrinsic value of restricted stock vested and released	$ 149,800,000	$ 130,100,000	$ 117,200,000
Unrecognized compensation cost related to unvested awards	$ 274,700,000
Unrecognized compensation cost expected to recognized over weighted average period, in years	2 years 7 months 6 days
Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested awards	$ 36,500,000
Unrecognized compensation cost expected to recognized over weighted average period, in years	2 years 8 months 12 days
Restricted Stock \| Independent Director \| Common stock:
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, years	1 year
Initial equity grant value	$ 400,000
Average closing price of common stock, trailing period	30 days
Restricted Stock Unit Awards with non-Revenue based Performance Conditions
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value per RSU granted (in dollars per share)	$ 89.22	$ 78.27	$ 78.09
Unrecognized compensation cost related to unvested awards	$ 10,900,000
Unrecognized compensation cost expected to recognized over weighted average period, in years	1 year 3 months 18 days
Award vesting service period	3 years
Restricted Stock Unit Awards with non-Revenue based Performance Conditions \| Strategic Goal Target
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, years	3 years
Restricted Stock Unit Awards with non-Revenue based Performance Conditions \| Non-GAAP Income Target
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, years	3 years
Restricted Stock Unit Awards with non-Revenue based Performance Conditions \| Internal Financial Measure Target
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, years	3 years
Restricted Stock Unit Awards with non-Revenue based Performance Conditions \| Regulatory Milestone
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, years	3 years
Restricted Stock Unit Awards with non-Revenue based Performance Conditions \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares earned range	50%
Restricted Stock Unit Awards with non-Revenue based Performance Conditions \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares earned range	200%
Restricted Stock Unit Awards with Market Conditions
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value per RSU granted (in dollars per share)	$ 132.56	$ 124.67	$ 117.52
Unrecognized compensation cost related to unvested awards	$ 18,000,000
Unrecognized compensation cost expected to recognized over weighted average period, in years	1 year 4 months 24 days
Award vesting service period	3 years
Ceiling achievement level	100%
Restricted Stock Unit Awards with Market Conditions \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares earned range	0%
Annual shareholder return multiplier	50%
Restricted Stock Unit Awards with Market Conditions \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares earned range	200%
2017 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	39.5
2017 Equity Incentive Plan \| Restricted Stock with Service Based Vesting Conditions
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, years	4 years
2017 Equity Incentive Plan \| Restricted Stock Unit Awards with Performance-Based Vesting Conditions
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, years	3 years
Initial time period vesting requirements	3 years
2017 Equity Incentive Plan \| Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, years	4 years
Initial time period vesting requirements	12 months
Contractual term of stock option awards, years	10 years

EQUITY COMPENSATION PLANS AND_4

EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 207,099	$ 196,308	$ 197,263
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	17,604	17,709	22,357
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	65,714	61,702	67,196
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 123,781	$ 116,897	$ 107,710

EQUITY COMPENSATION PLANS AND_5

EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restricted Stock with Service Based Vesting Conditions
Shares
Non-vested units, beginning balance (in shares)	4,519,746
Granted (in shares)	2,150,561
Vested (in shares)	(1,666,477)
Forfeited (in shares)	(300,005)
Non-vested units, ending balance (in shares)	4,703,825	4,519,746
Weighted Average Grant Date Fair Value
Non-vested units, beginning balance (in dollars per share)	$ 79.55
Granted (in dollars per share)	88.96	$ 79.43	$ 78.46
Vested (in dollars per share)	80.68
Forfeited (in dollars per share)	81.35
Non-vested units, ending balance (in dollars per share)	$ 83.39	$ 79.55
Restricted Stock Unit Awards with non-Revenue based Performance Conditions
Shares
Non-vested units, beginning balance (in shares)	447,662
Granted (in shares)	230,019
Vested (in shares)	(231,346)
Forfeited (in shares)	(10,235)
Non-vested units, ending balance (in shares)	436,100	447,662
Weighted Average Grant Date Fair Value
Non-vested units, beginning balance (in dollars per share)	$ 78.78
Granted (in dollars per share)	89.22	$ 78.27	78.09
Vested (in dollars per share)	78.30
Forfeited (in dollars per share)	78.36
Non-vested units, ending balance (in dollars per share)	$ 83.33	$ 78.78
Restricted Stock Unit Awards with Market Conditions
Shares
Non-vested units, beginning balance (in shares)	396,120
Granted (in shares)	261,570
Vested (in shares)	(248,940)
Forfeited (in shares)	(4,850)
Non-vested units, ending balance (in shares)	403,900	396,120
Weighted Average Grant Date Fair Value
Non-vested units, beginning balance (in dollars per share)	$ 119.61
Granted (in dollars per share)	132.56	$ 124.67	$ 117.52
Vested (in dollars per share)	116.05
Forfeited (in dollars per share)	121.04
Non-vested units, ending balance (in dollars per share)	$ 128.95	$ 119.61

EQUITY COMPENSATION PLANS AND_6

EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Fair Value of TSR-RSUs Granted Assumptions (Details) - Restricted Stock Unit Awards with Market Conditions - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value (in dollars per share)	$ 132.56	$ 124.67	$ 117.52
Expected volatility, minimum	22.40%	24.50%	24.70%
Expected volatility, maximum	152.10%	157.60%	161.70%
Dividend yield	0%	0%	0%
Expected term	2 years 9 months 18 days	2 years 9 months 18 days	2 years 9 months 18 days
Risk-free interest rate	3.80%	2%	0.30%

EQUITY COMPENSATION PLANS AND_7

EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 30, 2022
Shares
Options outstanding beginning balance (in shares)	5,943,535
Granted (in shares)	704,589
Exercised (in shares)	(837,623)
Expired and forfeited (in shares)	(90,370)
Options outstanding ending balance (in shares)	5,720,131
Options unvested (in shares)	1,260,219
Exercisable (in shares)	4,459,912
Weighted Average Exercise Price
Outstanding beginning balance (in dollars per share)	$ 82.41
Granted (in dollars per share)	89.47
Exercised (in dollars per share)	68.82
Expired and forfeited (in dollars per share)	82.69
Outstanding ending balance (in dollars per share)	85.26
Options unvested (in dollars per share)	84.63
Exercisable (in dollars per share)	$ 85.44
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining years, options outstanding	5 years
Weighted average remaining years, options unvested	8 years 8 months 12 days
Weighted average remaining years, exercisable	4 years
Aggregate intrinsic value, options outstanding	$ 74,704	$ 132,395
Aggregate intrinsic value, options unvested	15,139
Aggregate intrinsic value, exercisable	$ 59,566
Closing price of common stock (in dollars per share)			$ 96.42

EQUITY COMPENSATION PLANS AND_8

EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Fair Value of Stock Options Granted Assumptions (Details) - Option	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	37.80%	38.10%	39.40%
Expected volatility, maximum	40.30%	40.50%	41.60%
Dividend yield	0%	0%	0%
Risk-free interest rate, minimum	3.50%	2.10%	0.70%
Risk-free interest rate, maximum	4.60%	4.20%	1.30%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	4 years 8 months 12 days	4 years 8 months 12 days	4 years 8 months 12 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years 2 months 12 days	6 years 1 month 6 days	6 years

EQUITY COMPENSATION PLANS AND_9

EQUITY COMPENSATION PLANS AND STOCK-BASED COMPENSATION - Schedule of Fair Value of Stock Purchase Rights Granted Under the ESPP (Details) - Employee Stock Purchase Plan	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	24%	28.60%	23.70%
Expected volatility, maximum	48%	69.20%	69.20%
Dividend yield	0%	0%	0%
Risk-free interest rate, minimum	0.06%	0.04%	0.04%
Risk-free interest rate, maximum	5.50%	4.80%	2.40%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 months	6 months	6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	2 years	2 years	2 years

OTHER EMPLOYEE BENEFITS (Detail

OTHER EMPLOYEE BENEFITS (Details) - BioMarin Retirement Savings Plan - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Company's contribution to match employees contribution	100%
Employer contribution of maximum percentage over employee's annual compensation	6%
Company's contribution from employment commencement	$ 32.7	$ 30.8	$ 31.6

INCOME TAXES - Schedule of Prov

INCOME TAXES - Schedule of Provision for (Benefit from) Income Taxes Based on Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
U.S. Source	$ (453,840)	$ (299,403)	$ (259,258)
Non-U.S. Source	642,403	448,979	183,908
INCOME (LOSS) BEFORE INCOME TAXES	$ 188,563	$ 149,576	$ (75,350)

INCOME TAXES - Schedule of Comp

INCOME TAXES - Schedule of Components of Provision for (Benefit from) Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Provision for (benefit from) income taxes
Federal	$ 25,120	$ 12,798	$ (2,038)
State and local	5,098	5,058	1,339
Foreign	35,681	42,246	5,037
Current income tax expense, total	65,899	60,102	4,338
Provision for (benefit from) deferred income taxes:
Federal	(70,754)	(79,270)	(29,895)
State and local	(8,030)	(5,143)	(1,230)
Foreign	33,803	32,326	15,517
Deferred income tax expense (benefit), total	(44,981)	(52,087)	(15,608)
Provision for (benefit from) income taxes	$ 20,918	$ 8,015	$ (11,270)

INCOME TAXES - Schedule of Reco

INCOME TAXES - Schedule of Reconciliation of Statutory Federal Income Tax Benefit to Effective Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Contingency [Line Items]
Federal statutory income tax rate	$ 39,598	$ 31,412	$ (15,824)
State and local taxes	(3,614)	(1,017)	509
Orphan Drug & General Business Credit	(39,535)	(35,674)	(29,363)
Stock compensation expense	2,209	6,433	7,859
Foreign Source Income Subject to US Tax	47,721	(5,644)	16,878
Foreign tax rate differential	(69,987)	(4,051)	(16,971)
Section 162(m) limitation	9,699	6,577	6,304
Tax Reserves	27,296	18,043	15,530
Intra-entity transfer of assets	5,019	(18,752)	(3,920)
Valuation allowance/deferred benefit	3,723	7,851	6,821
Other	(1,211)	2,837	907
Provision for (benefit from) income taxes	20,918	8,015	(11,270)
Valuation allowance	$ 119,230	$ 116,299
Dutch
Income Tax Contingency [Line Items]
Valuation allowance			$ 9,300

INCOME TAXES - Schedule of Co_2

INCOME TAXES - Schedule of Components of Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Net deferred tax assets:
Net operating loss carryforwards	$ 19,025	$ 20,657
Tax credit carryforwards	524,652	555,319
Accrued expenses, reserves, and prepaids	107,485	88,697
Intangible assets	789,479	836,402
Capitalized research and development expenses	216,975	103,212
Stock-based compensation	48,744	49,472
Lease liabilities	7,857	5,757
Inventory	18,914	22,726
Other	1,113	5,596
Valuation allowance	(119,230)	(116,299)
Total deferred tax assets	1,615,014	1,571,539
Net deferred tax liabilities
Joint venture basis difference	(1,111)	(745)
Acquired intangibles	(1,026)	(1,138)
ROU Assets	(6,917)	(5,347)
Property, plant and equipment	(60,151)	(58,897)
Total deferred tax liabilities	(69,205)	(66,127)
Net deferred tax assets	$ 1,545,809	$ 1,505,412

INCOME TAXES - Schedule of Net

INCOME TAXES - Schedule of Net Operating Loss and Tax Credit Carryforwards (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Federal
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 3,296
Federal R&D and orphan drug credit carryforwards	555,074
State
Income Tax Contingency [Line Items]
Net operating loss carryforwards	208,592
Federal R&D and orphan drug credit carryforwards	169,600
Dutch \| Foreign
Income Tax Contingency [Line Items]
Dutch net operating loss carryforwards	$ 31,361

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) $ in Millions	12 Months Ended
INCOME TAXES - Narrative (Details) $ in Millions	Dec. 31, 2023 USD ($)
Income Tax Contingency [Line Items]
Unrecognized tax benefits that would affect the effective tax rate if recognized	$ 266.5
Undistributed earnings of foreign subsidiaries	$ 15.1
Minimum
Income Tax Contingency [Line Items]
Income tax statute of limitations period	3 years
Maximum
Income Tax Contingency [Line Items]
Income tax statute of limitations period	5 years
State
Income Tax Contingency [Line Items]
Research credit carry forward	$ 169.6

INCOME TAXES - Schedule of Re_2

INCOME TAXES - Schedule of Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of period	$ 232,856	$ 205,095
Additions based on tax positions related to the current year	41,473	26,762
Additions for tax positions of prior years	3,127	1,017
Lapse of statute of limitations	0	(18)
Balance at end of period	$ 277,456	$ 232,856

EARNINGS (LOSS) PER COMMON SH_3

EARNINGS (LOSS) PER COMMON SHARE - Schedule of Computation of Basic and Diluted Earnings (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net income (loss)	$ 167,645	$ 141,561	$ (64,080)
Denominator:
Weighted-average common shares outstanding, basic (in shares)	187,834	185,266	182,852
Effect of dilutive securities:
Weighted-average common shares outstanding, diluted (in shares)	191,595	188,963	182,852
Earnings (loss) per common share, basic (in dollars per share)	$ 0.89	$ 0.76	$ (0.35)
Earnings (loss) per common share, diluted (in dollars per share)	$ 0.87	$ 0.75	$ (0.35)
Common stock issuable under the Company's equity incentive plans
Effect of dilutive securities:
Common stock issuable under the Company's equity incentive plans (in shares)	3,761	3,697	0

EARNINGS (LOSS) PER COMMON SH_4

EARNINGS (LOSS) PER COMMON SHARE - Schedule of Anti-Dilutive Common Stock Excluded from Computation of Basic and Diluted Earnings (Loss) Per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total number of potentially issuable shares (in shares)	16,407	16,483	20,785
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes) \| Convertible Senior Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares issued if converted (in shares)	4,000
1.250% senior subordinated convertible notes due in May 2027 (the 2027 Notes) \| Convertible Senior Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares issued if converted (in shares)	4,400
Common stock issuable under the Company's equity incentive plans
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total number of potentially issuable shares (in shares)	8,072	8,148	12,450
Common stock issuable under the Company’s convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total number of potentially issuable shares (in shares)	8,335	8,335	8,335

LICENSE AND COLLABORATION AGR_2

LICENSE AND COLLABORATION AGREEMENTS (Details) $ in Thousands, € in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2019 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 2,419,226		$ 2,096,039	$ 1,846,275
Impairment loss		10,538		2,050	$ (11,846)
FIRDAPSE \| Disposal Group, Disposed of by Sale, Not Discontinued Operations
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties on net product sales, minimum						7%
Royalties on net product sales, maximum						10%
Exclusive Licensing Agreement for Tralesinidase Alfa
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 3,000
Investment in equity				$ 12,600
Exclusive Licensing Agreement for Tralesinidase Alfa \| Variable Interest Entity, Not Primary Beneficiary
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Minority equity ownership	15%
A&R Kuvan Agreement \| Merck Serono \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Business acquisition contingent consideration potential cash payments upon achievement of sales milestone \| €			€ 60
Pegvaliase Agreement \| Merck Serono
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Business acquisition, cash paid \| €			€ 125
Research and Collaboration Agreement With Third Party
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Impairment loss		$ 11,900

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) $ in Millions	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details) $ in Millions	Dec. 31, 2023 USD ($) third_party	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Commitments and Contingencies [Line Items]
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones	$ 763.3
Amount due in 2024	30.1
Purchase commitment	354.1
Purchase commitment expected to be paid in 2024	325.9
Shareholder vs BioMarin Pharmaceutical Inc
Commitments and Contingencies [Line Items]
Estimated long-term loss contingency		$ 39	$ 13
Amount awarded to other party released	39
Early Stage Development Program \| Third Party
Commitments and Contingencies [Line Items]
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones	$ 591.5
Number of third parties \| third_party	2